Previous Article | Next Article 
Molecular and Cellular Biology, October 2001, p. 6369-6386, Vol. 21, No. 19
0270-7306/01/$04.00+0 DOI: 10.1128/MCB.21.19.6369-6386.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Interferon Regulatory Factor 4 Contributes to
Transformation of v-Rel-Expressing Fibroblasts
Radmila
Hrdli
ková,
Ji
í
Nehyba, and
Henry R.
Bose Jr.*
Section of Molecular Genetics and
Microbiology and Institute for Cellular and Molecular Biology,
University of Texas at Austin, Austin, Texas 78712-1095
Received 8 March 2001/Returned for modification 22 April
2001/Accepted 27 June 2001
 |
ABSTRACT |
The avian homologue of the interferon regulatory factor 4 (IRF-4)
and a novel splice variant lacking exon 6, IRF-4
E6, were isolated
and characterized. Chicken IRF-4 is expressed in lymphoid organs, less
in small intestine, and lungs. IRF-4
E6 mRNA, though less abundant
than full-length IRF-4, was detected in lymphoid tissues, with the
highest levels observed in thymic cells. IRF-4 is highly expressed in
v-Rel-transformed lymphocytes, and the expression of IRF-4 is increased
in v-Rel- and c-Rel-transformed fibroblasts relative to control cells.
The expression of IRF-4 from retrovirus vectors morphologically
transformed primary fibroblasts, increased their saturation density,
proliferation, and life span, and promoted their growth in soft agar.
IRF-4 and v-Rel cooperated synergistically to transform fibroblasts.
The expression of IRF-4 antisense RNA eliminated formation of soft agar
colonies by v-Rel and reduced the proliferation of v-Rel-transformed
cells. v-Rel-transformed fibroblasts produced interferon 1 (IFN1),
which inhibits fibroblast proliferation. Infection of fibroblasts with
retroviruses expressing v-Rel resulted in an increase in the mRNA
levels of IFN1, the IFN receptor, STAT1, JAK1, and 2',5'-oligo(A)
synthetase. The exogenous expression of IRF-4 in v-Rel-transformed
fibroblasts decreased the production of IFN1 and suppressed the
expression of several genes in the IFN transduction pathway. These
results suggest that induction of IRF-4 expression by v-Rel likely
facilitates transformation of fibroblasts by decreasing the induction
of this antiproliferative pathway.
 |
INTRODUCTION |
v-rel, which is
derived from the c-rel proto-oncogene, is the acutely
transforming oncogenic member of the Rel/NF-
B family (32,
42). The Rel/NF-
B family of transcription factors regulate gene expression from promoters or enhancers containing
B
binding sites (GGGRNNYYCC, where R is a purine, Y is a pyrimidine, and N is any nucleotide) (7, 85). Rel/NF-
B
proteins coordinate the expression of genes involved in natural and
acquired immunity (56). In addition, the Rel/NF-
B
proteins participate in the regulation of other processes such as
apoptosis and embryonic development (8, 15, 29, 34, 36,
51). The function of Rel/NF-
B family members has been highly
conserved during vertebrate evolution, and essentially the same five
transcription factors
RelA, RelB, c-Rel, NF-
B1 (p50), and NF-
B2
(p52)
are present in birds and mammals (30).
Altered regulation of Rel/NF-
B activity has been linked to several
pathological processes, including oncogenesis (25, 90). While rearrangements and amplifications of Rel/NF-
B genes have been
found in human tumors, c-Rel is the only family member for which acute
oncogenesis has been demonstrated (43, 59, 78). Mutations
are necessary to activate c-Rel's oncogenic potential. The most highly
oncogenic c-Rel mutant, v-Rel, transforms two different cell types,
fibroblasts and cells of hematopoietic origin (26, 62).
v-Rel-transformed fibroblasts acquire a distinct morphology, are
capable of limited growth in soft agar, have a prolonged life span, and
induce solid tumors (26, 59, 72, 74). Transformed
hematopoietic cells become immortalized, and most of them form
aggressive lymphomas in vivo. The ability of v-Rel to transform a
particular cell type depends on its ability to induce or repress a
specific set of genes. Approximately two dozen genes which exhibit
elevated expression in v-Rel-transformed cells have been identified
(32, 42). These genes encode cytokines, cell surface
receptors, chaperones, genes involved in oxidative metabolism,
apoptosis, and various transcription factors.
Interferon regulatory factors (IRFs) are transcription factors which
bind to promoter elements that contain an AANNGAAA consensus sequence and either stimulate or repress transcription of these target
genes (27). IRFs, originally identified as regulators of
interferons (IFNs) and IFN-stimulated genes, are involved in the
regulation of natural immunity against viruses, acquired
immunity, apoptosis, and embryogenesis, functions also
attributed to the Rel/NF-
B family (40, 66, 83, 88).
Nine IRF family members have been described in mammals: IRF-1 through
7, IRF-8, also called IFN consensus sequence-binding protein (ICSBP),
and IRF-9, originally described as IFN-stimulated gene factor 3-
(ISGF3-
). All IRF proteins possess a highly conserved DNA-binding
domain with five regularly spaced tryptophans at their N termini. The C
termini contain sequences involved in transcriptional activation and
repression (66, 83). The IRF members except IRF-1 and
IRF-2 have a conserved IRF association domain, which mediates
interactions with both other IRF proteins and transcription factors of
other families (83).
IRFs transactivate multiple genes that encode proteins with diverse
effects on cell proliferation and differentiation, including genes of
the IFN family. IFNs are multifunctional cytokines that play an
important role in the induction of antiviral responses, cell growth,
differentiation, and immunomodulation (40, 103). Type I
IFNs (mammalian IFN-
, -
, -
, and -
as well as avian IFN1 and
IFN2) are produced by a variety of cell types, while type II IFNs
(IFN-
) are secreted primarily by T cells and natural killer cells
(101, 102). IFN type I cytokines are the major IFNs that
respond to virus infection. Viral infection activates IRF, Rel/NF-
B,
and bZIP transcription factors, leading to IFN synthesis
(66). Secreted IFNs exert their effect by binding to cell
surface receptors and activating the JAK/STAT signal transduction pathway, leading to DNA binding by a complex composed of STAT1, STAT2,
and IRF-9 (103). This results in activation of the
IFN-stimulated genes, which exert an antiviral and, in many cell types,
antiproliferative effect (49).
Several IRF proteins have been associated with the development of
cancer, and viral IRF homologues are present in oncogenic herpesviruses
(28). IRF-1 and IRF-8 may function as antioncogenes, while
IRF-2 and IRF-4 have some characteristics of oncogenes (39, 41,
47, 97). IRF-4 is activated by Tax in adult T-cell leukemia and
is overexpressed in multiple myelomas as a result of a translocation of
the IRF-4 gene into the immunoglobulin M (IgM) heavy-chain locus
(47, 108, 110). In contrast to other IRF family members, IRF-4 is not induced by viral infection or IFNs but by proliferative stimuli (13, 68, 108). Furthermore, while most IRFs are
expressed in a variety of cell types, IRF-4 is expressed predominantly
in B cells and in activated T cells (66). Mice deficient
in IRF-4 have defects principally in the development and function of B and T lymphocytes (71). However, IRF-4 is also detected in
macrophages, lens cells, and melanocytes, suggesting that it may also
be involved in the regulation of cells other than lymphocytes
(35, 63, 64, 67, 94). IRF-4 inhibits the expression of
some IFN-induced genes, presumably by interfering with the action of
other IRFs (12, 68, 108).
In this work, we demonstrate that IRF-4 overexpression transforms
primary chicken embryonic fibroblasts (CEFs). IRF-4 also synergistically cooperates with v-Rel in transformation of CEFs, while
antisense IRF-4 expression inhibits v-Rel-mediated transformation. v-Rel transformation of CEFs is associated with the induction of
expression of IFN1, the IFN1 receptor, STAT1, JAK1, and the IFN target
gene 2',5'-oligo(A) synthetase (OAS). IRF-4 expression, which is
induced in CEFs following infection by v-Rel- and c-Rel-expressing viruses, alters the antiviral gene expression program and likely contributes to transformation of fibroblasts by decreasing the negative
antiproliferative effect of the v-Rel-induced antiviral program.
 |
MATERIALS AND METHODS |
Cloning of chicken IRF-4 cDNA.
An 858-bp fragment of chicken
IRF-4 was cloned by reverse transcription (RT)-PCR from chicken splenic
mRNA. First-strand cDNA synthesis was carried out with avian
myeloblastosis virus (AMV) reverse transcriptase (Promega, Madison,
Wis.) and a locking-docking primer (LDP) specific for poly(A)
RNA (5'-AATCTAGAATGTCGACATGCGCGCTTTTTTTTTTTTTTTTVN-3', where
V is an A, C, or G) at 42°C. Degenerate PCR primers I4-1 (5'-CACCTCGAGAAYGAYTTYGARGARYTNGT-3') and I4-2
(5'-GCAGCGCGCGGRAAYTCYTCNCCRAARCA-3') were designed based on
the similarity between the amino acid sequences of human and mouse
IRF-4 as well as differences in the sequence of the closest IRF family
member, chicken IRF-8 (50). Two rounds of PCR were carried
out with these primers using Taq DNA polymerase (Gibco-BRL
Life Technologies, Grand Island, N.Y.). The second round used a 1-µl
aliquot of the first-round PCR synthesis as a template. Each round
consisted of 35 cycles of 1 min of denaturation at 94°C, 1 min of
annealing, and 2 min of extension at 72°C. The annealing temperature
was 55°C in the first round and 45°C in the second. The resulting
858-bp PCR fragment was cloned into the pGEM-T vector (Promega),
creating pIRF858, and sequenced. The sequence of the 858-bp fragment,
which corresponded to amino acids 105 to 392 of human IRF-4, was used
to design an additional primer
(5'-GGTACCAGGTTGCTCTGTGCTTCGGAGAG-3') to amplify the 3' region (1,920 bp) of the IRF-4 cDNA from chicken bursal mRNA by 3'SMART
RACE PCR technology (Clontech Laboratories, Palo Alto, Calif.). The PCR
products were cloned into the pGEM-T Easy vector (Promega), creating
pIRF4CT, and sequenced.
In order to obtain the 5' end of IRF-4 cDNA, the combined sequences of
both PCR fragments and the N-terminal protein sequence of human IRF-4
were used to screen chicken expressed sequence tag (EST) databases
(2, 106). Among the several positive ESTs, we identified
one clone, pat.pk0027.c10.f (accession number AI980577), isolated from
a concanavalin A (ConA)-activated chicken splenic T-cell library, which
encoded the N terminus of chicken IRF-4. The complete sequencing of
this cDNA clone determined that its 3' region is 99.7% identical to
the sequences of our PCR clones, with one notable exception. The
pat.pk0027.c10.f clone was missing a region encoding 36 amino acids in
the middle of the open reading frame (ORF) of IRF-4, suggesting that it
may represent an alternatively spliced IRF-4 variant. To obtain the
full ORF of IRF-4 including these 36 amino acids, primers which flanked
the ORF on both sides (5'-GAGCTGGTCACAGAGGTGGTGCTCAG-3' and
5'-TGCTATCCAGATCAGCTCCTCCACTC-3') were used to PCR-amplify
the cDNA from bursa as well as from ConA-activated splenic cells.
Plasmids containing the cloned PCR fragments were designated pGE.IRF4-1
and pGE.IRF4-2 and sequenced.
Plasmids.
The pATH-I4#6 bacterial expression plasmid encodes
a TrpE/IRF-4 fusion protein. This plasmid was created by cloning the
PvuII-BssHII (828 nucleotides [nt]) fragment of
pIRF858 between the SmaI and HindIII sites of
pATH1 using a double-stranded adapter
(5'-CGCGCGCTGAGTGACTGAGCTCA-3' and
5'-AGCTTGAGCTCAGTCACTCAGCG-3') containing a
BssHII site, three stop codons in all reading frames, and a
HindIII site (54).
pTZ-IRF-4

E6 was created by cloning the
Eco72I-
BglII fragment of pat.pk0027.c10
into pTZ-18R which was modified by the introduction
of a
double-stranded oligonucleotide adapter
(5'-AATTGCTCGAGCACGTGGAATTCAGATCTATTCGCCATTCCTCTATTCAAGATAAGCGCGC-3'
and
5'-TCGAGCGCGCTTATTCTTGAATAGAGGAATGGCGAATAGATCTGAATT CCAGTGCTCGAGC-3')
between the
EcoRI and
HindIII sites. The
adapter contained an
XhoI site, an
Eco72I site,
the sequence encoding amino acids 436
to 445 of IRF-4 (containing a
BglII site) followed by a stop codon,
and a
BssHII site. pTZ-IRF-4, which contains the full-length
variant
of IRF-4, was obtained by replacing the
ApaI-
PstI region of pTZ-IRF-4

E6
with an
ApaI-
PstI fragment from the pIRF858
clone.
The REV-T-based pREV-0 and pREV-TW (containing v-
rel)
reticuloendotheliosis virus (REV)-based retroviral vectors have been
described previously (
44,
81). The retroviral vector pRSN
was created by cloning an adapter containing
NotI,
XhoI,
MfeI,
and
SpeI sites
(5'-TCGACGCGGCCGCCTCGAGCAATTGACTAGTG-3' and
5'-CGCGCACTAGTCAATTGCTCGAGGCGGCCGCG-3')
between the
XhoI and
BssHII sites in pREV-0. The pCSV11S3
plasmid
encodes an infectious genome of chicken syncytial virus (CSV)
(
23). The pREV-IRF-4 and pREV-IRF-4

E6 retroviral
vectors were
obtained by cloning the
XhoI-
BssHII
fragments of pTZ-IRF-4 and
pTZ-IRF-4

E6 into pREV-0. The retroviral
vector pREV-antiIRF-4,
which expresses IRF-4 in the antisense
orientation, was obtained
by cloning an
XhoI-
SpeI
fragment containing nucleotides 73 to
1429 of the IRF-4 cDNA from
pTZ-IRF-4 into the retroviral vector
pRSN (Fig.
1A). The pRCAS plasmid encodes a
replication-competent
avian sarcoma-leukemia virus (
46).
pDS3 and pREP-A plasmids
were used to prepare DS3 virus
(
84). Plasmids were cut with
SalI and ligated
to form concatemers before transfection of CEFs.
pRCAS, pDS3, and
pREP-A plasmids are derived from the same genomic
clone of
Schmidt-Ruppin Rous sarcoma virus (
20). pRCASc-Rel
was
obtained by cloning of an
HpaII-
HpaII
c-
rel fragment from
pBSc-rel#29 into a
ClaI site
in the RCAS vector (
16). pDSv-Rel
was constructed by
insertion of v-
rel into pDS3 as described previously
(
58). To prepare DSv-Rel virus, pDSv-Rel and pREP-A
plasmids
were cut with
SalI and ligated to form concatemers
before transfection
of CEFs. Plasmid pcDNAchIFN1 was used for the
production of IFN1
in COS-1 cells as described (
99,
102).

View larger version (89K):
[in this window]
[in a new window]
|
FIG. 1.
Sequence and selected features of chicken IRF-4 cDNA.
(A) Nucleotide and predicted amino acid sequence. The position of exon
6, which is absent in the splice variant of IRF-4, is
indicated by a single bold underline. The open box in the 3' UTR
identifies a 46-bp element that is conserved between the chicken,
human, and mouse IRF-4 cDNAs. The polyadenylation signal is denoted by
a double underline. The last C nucleotide at position 3178 was followed
by tracts of multiple A nucleotides in two independently isolated
clones (pIRF4CT and pat.pk0027.c10 clones). (B) Putative translation
start sites in chicken (ch), human (h), and mouse (m) IRF-4 cDNA
sequences. Asterisks mark positions that are identical in all three
sequences. The boxes around each of the two possible ATG start codons
circumscribe a 10-bp element homologous to the Kozak consensus sequence
(57). Identical nucleotides are found in both potential
start sites at the most critical positions: G at position 3 and A at
position +1 relative to the ATG codon. The positions of the first
nucleotide shown are indicated on the left side with respect to the
full-length cDNA sequences. (C) The 46-bp conserved element in the 3'
UTR of chicken (ch), human (h), and mouse (m) IRF-4 cDNAs. This
conserved motif is preceded by a stretch of 82 nt that also shows
significant, albeit limited, similarity to the corresponding regions of
the mammalian cDNAs (data not shown). For asterisks and position
numbers, see legend to panel B.
|
|
The following plasmids were used for expression of various oncogenes in
CEF cell cultures. pAPrP-C plasmid containing the
genome of the Prague
strain of Rous sarcoma virus was used for
expression of
v-
src, and a pBUR2-II plasmid containing the genome
of UR2
sarcoma virus was used for the expression of v-
ros
(
70,
113). DS3 virus was used for the
replication-defective UR2 as
a helper. Additional oncogenes were
expressed using pRCAS(A) or
pRCAS-BP(A) retroviral vectors. These
oncogenes included the activated
chicken c-Ha-
ras
(tfch-
ras), the oncogenic form of phosphatidylinositol-3
kinase (PI-3 kinase) (v-
p3k), v-
jun,
v-
qin, and v-
ski (
11,
17-19,
33).
Chickens, cell lines, and tissue culture.
Embryonated eggs
of specific-pathogen-free White Leghorn chickens were obtained from
Hy-Vac, Adel, Iowa (SPF-SC strain), and Charles River SPAFAS, North
Franklin, Conn. (SPAFAS strain). Most of the work presented in this
article was done with fibroblasts and animals of SPF-SC strain. Cells
from SPAFAS birds were used only for the cloning of pGE.IRF4-2 cDNA
clone, the detection of IRF-4 protein in DSv-Rel-transformed cells, and
the experiment shown in Fig. 9B. CEFs were prepared from 10- or
11-day-old embryos. Cells were cultured with Dulbecco's modified
Eagle's medium (DMEM) supplemented with 5% newborn calf serum
(Atlanta Biologicals, Norcross, Ga.), 5% chicken serum (Gibco-BRL Life
Technologies, Grand Island, N.Y.), 100 U of penicillin, and 50 µg of
streptomycin per ml. Secondary cultures of CEFs were used for
transfection of plasmid DNA by a modified calcium phosphate method as
described previously (44). pREV-0-based plasmids (30 µg)
together with pCSV11S3 (1 µg), pRCAS-based plasmids (30 µg), pDS3-
or pDSv-rel-pREP-A concatemers (4 µg), or pCSV11S3 (1 µg) alone
were used for transfection per 100-mm-diameter tissue culture dish of
CEFs. Viruses were harvested between 5 and 7 days after transfection,
and the infectious titers of Rel-expressing viruses and CSV were
determined by an immunochemical titration assay (44, 104).
The simian COS-1 cell line was used for production of recombinant IFN1
(
69). QT6 is a quail fibroblast cell line obtained
by
chemical mutagenesis (
76). The 1757 duck cell line was
derived
from a duck sarcoma induced by avian leukosis virus (ALV)
(
82).
All other cell lines used are of chicken origin.
DT40 is a B-cell
line established from an ALV-infected chicken bearing
a bursa-derived
lymphoid tumor (
6). DT40 cells are
transformed bursal stem
cells which are continuously undergoing
immunoglobulin gene diversification
(
53). The DT95 cell
line is also derived from a chicken with
an ALV-induced lymphoid
leukosis and exhibits a more mature phenotype,
including secretion of
IgM (
6). MSB-1 and RP-1 are T-cell lines
established from
a Marek's disease virus-induced lymphoma, 123/12
is a
v-
rel-transformed B-cell line, 160/2 is a
v-
rel-transformed
T-cell line, and 123/6T is a
macrophage-like v-
rel-transformed
cell line (
3,
44,
80). AEV-1 is an avian erythroblastosis
virus-transformed
erythroid cell line (
89). BM-2 is a macrophage-like
cell
line derived by transformation of yolk sac cells by AMV
(
77).
C4-1 cells are a lymphoid non-virus-producing
S2A3v-
rel-transformed
cell line (
93,
111). The
fibroblastoid cell line 26T6 was derived
from a sarcoma induced by
REV-Cgi, which expresses a c-
rel mutant
(
43).
Transformation assay.
Transformed and control fibroblasts
(105) were plated in 5 ml of DMEM containing 15%
chicken serum and 0.35% Noble agar per 60-mm-diameter dish containing
a bottom layer of 0.75% agar. Cells were refed with additional soft
agar medium every 10 days. Plates were scored for the development of
colonies 3 weeks after plating.
Preparation and treatment of white blood cells, lymphocytes, and
bone marrow cells.
Peripheral white blood cells and
lymphocyte-enriched fractions from bursa, thymus, and spleen used to
prepare RNA for Northern and RT-PCR analyses were isolated using
Histopaque (Sigma Chemical Co., St. Louis, Mo.). A single-cell
suspension of bursal lymphocytes for the experiment shown in Fig. 3 was
obtained by passing minced tissue through a nylon mesh followed by a
nylon cell strainer (100 µm; Becton Dickinson Labware,
Franklin Lakes, N.J.). Cells were stimulated with
phorbol-12-myristate-13-acetate (PMA) (1 µg/µl) (Sigma). Bone
marrow was isolated from femur and tibiotarsus bones. The bones were
cut longitudinally with a razor blade, and the entire contents of the
bone cavity were scraped out and used for RNA preparation.
Antisera.
The AI4-6 polyclonal antiserum was raised in a
rabbit immunized with a TrpE/IRF-4 fusion protein purified from C600
bacteria transformed by the pATH-I4#6 expression plasmid. The
TrpE/chIRF-4 fusion protein contains amino acids 112 to 386 of chicken
IRF-4. Monoclonal antibody HY87 is specific for avian c-Rel and v-Rel (44). The goat anti-mouse IgG1 and goat anti-rabbit IgG
biotinylated antibodies were purchased from Southern Biotechnology
Associates, Inc., Birmingham, Ala. The monoclonal antibody 8A9, which
recognizes chIFN1 but not chIFN2, was a generous gift from P. Staeheli
(88a).
Western analysis.
Western analysis was performed as
described previously (44). Briefly, harvested cells were
washed, resuspended, and boiled in sodium dodecyl sulfate (SDS) sample
buffer, and proteins were separated on an SDS-polyacrylamide gel using
a Mini-Protean II apparatus (Bio-Rad Laboratories, Hercules,
Calif.). Proteins were transferred to a PolyScreen polyvinylidene
difluoride membrane (NEN Life Science Products, Inc., Boston, Mass.)
and sequentially reacted with rabbit polyclonal antiserum AI4-6
or monoclonal antibody HY87, goat anti-mouse IgG1 or goat anti-rabbit
IgG biotinylated antibodies, and streptavidin-linked alkaline
phosphatase (Roche Molecular Biochemicals, Indianapolis, Ind.).
Proteins were visualized by an enzymatic reaction using
5-bromo-4-chloro-3-indolylphosphate and 4-nitro blue tetrazolium
chloride as substrates (Roche Molecular Biochemicals). Calibrated
prestained molecular size markers from Bio-Rad Laboratories were used.
Nuclear and cytoplasmic fractions of CEFs were prepared in hypotonic
buffer (50 mM Tris-HCl [pH 8], 1.1 mM MgCl2,
0.5% Triton X-100) as previously described (75).
Northern analysis and probes.
Total RNA was isolated by
RNAwiz (Ambion, Austin, Tex.). RNA was separated by electrophoresis in
a 1% agarose gel in 20 mM MOPS
(3-[N-morpholino]propanesulfonic acid) buffer and
transferred to a HybondN+ membrane (Amersham Pharmacia Biotechnology,
Piscataway, N.J.). Parallel samples with ethidium bromide were analyzed
under identical conditions, and the gel was photographed. Filters were hybridized with [
-32P]dCTP-labeled DNA
fragments using UltraHyb solution (Ambion) at 55°C. The probes used
for hybridization were labeled by nick translation and are listed in
Table 1.
Semiquantitative RT-PCR.
Total RNA (5 µg) together with 1 µl of 10 µM LDP
(5'-AATCTAGAATGTCGACATGCGCGCTTTTTTTTTTTTTTTTVN-3') and 1 µl of 10 µM Smart II primer (Clontech Laboratories, Inc.) was
denatured for 10 min at 70°C in 11 µl of water. First-strand cDNA
synthesis was carried out with 15 U of ThermoScript RT (Gibco-BRL Life
Technologies), 2 µl of 10 µM deoxynucleoside triphosphate (dNTP)
mix, and 2 µl of 100 µM dithiothreitol at 55°C for 1 h. For
detection of IRF-4 and IRF-4
E6 by RT-PCR, 2.5 µl of the
first-strand synthesis reaction was used together with 1 µl of
Advantage cDNA polymerase mix (Clontech Laboratories, Inc.) and primers
FP572 (5'-AGGAGCAGCCATTGATGAACC-3') and BP878
(5'-CCTCTGGATAAGGGAAGATGACTTG-3'). PCRs were performed in a
DNA thermal cycler 480 (Perkin-Elmer, Inc., Boston, Mass.) as follows:
five cycles of 30 s at 94°C and 3 min at 72°C; five cycles of 30 s at 94°C, 30 s at 70°C, and 3 min at
72°C; and 25 to 30 cycles of 30 s at 94°C, 30 s at
65°C, and 3 min at 72°C.
The samples of RNA used for detection of IFN1 by RT-PCR were first
treated with DNase I ("DNA-free" reagent; Ambion) to remove
possible traces of DNA in the RNA preparations. First-strand synthesis
was performed as above. The primers used in the PCR were either
IFN13
and IFN15 (5'-CCTCCAGCTCCTCCGGGACATGGCTCC-3' and
5'-GTGTTCCCAGGCGCAGGCGCTGTAATCG-3'),
which are specific to
chicken IFN1, or GAPDH1 and GAPDH2
(5'-TCATCTGAAGGGTGGTGCTAAGCGTG-3'
and
5'-TCTGGGCAGCACCTCTGTCATCTCTC-3'), which are specific for
the chicken glyceraldehyde-3-phosphate dehydrogenase (GAPDH) gene
(
105). PCRs were performed as follows: five cycles of
30 s at
94°C and 3 min at 72°C; five cycles of 30 s at
94°C, 30 s at 70°C,
and 3 min at 72°C; and 10 to 30 cycles
of 30 s at 94°C, 30 s at
68°C, and 3 min at 72°C.
Nucleotide and protein sequence analysis.
The nucleotide
sequence of the chicken IRF-4 clones was compared with the databases of
GenBank, EMBL, DDBJ, and PDB utilizing a Blast 2.0 search engine
(http://www.ncbi.nlm.nih.gov/BLAST) (4, 5). The same
search engine was used to compare the protein encoded by the ORF of
chicken IRF-4 with the protein sequence databases. The sequences of all
IRFs similar to chicken IRF-4 were retrieved, and their amino acid
homology was more precisely evaluated using the ClustalX program
coupled with the MacBoxshade 2.15 analysis tool (48). The
following protein sequence files from Swiss-Prot, translated GenBank,
and DDJB databases were compared to the chicken IRF-4 sequence:
sp Q90876, sp P10914, sp P15314, sp P23570, sp Q98925, sp P14316,
sp P23906, sp Q14653, sp P70671, sp Q15306, sp Q64287, sp Q13568,
sp P56477, sp O14896, gb AAB36714.1, dbj BAA24349.1, sp Q92985,
sp P70434, sp Q90871, sp Q02556, sp P23611, sp Q00978,
sp Q61179, and sp Q90643. Nucleotide sequences in the 5' and 3'
untranslated regions (UTRs) of chicken IRF-4 cDNA were compared to
sequences of mammalian IRF-4 (GenBank U52682 and U11692) using FASTA and Macaw 2.0.5 alignment tools to determine homology (61, 86, 98). Possible PEST regions were evaluated by the
PEST-FIND program (available at
http://www.at.embnet.org/embnet/tools/bio/PESTfind/) (92).
Nucleotide sequence accession numbers.
The sequence of
chicken IRF-4 submitted to GenBank under accession number AF320331 is a
composite of two cDNA clones, pat.pk0027.c10 and pGE.IRF4-2. The
sequence of the IRF-4
E6 splice variant is based on the
pat.pk0027.c10 clone and was submitted in a separate file with
accession number AF320332. The four cDNA clones (pIRF858, pIRF4CT, and
pGE.IRF4-1 and -2) that were obtained by RT-PCR differed in overlapping
regions at a few nucleotide positions from pat.pk0027.c10 and from each
other. Because at least some of these differences are probably caused
by the low fidelity inherent to PCR, the sequence of pat.pk0027.c10 was
taken to be the standard, as this plasmid was isolated directly from a
plasmid-based cDNA library without a PCR amplification step. The
fidelity of the sequence in the exon 6 region, which is not present in
pat.pk0027.c10, is supported by the identity of this sequence in
two independently isolated PCR clones, pGE.IRF4-2 and pIRF858.
 |
RESULTS |
Cloning and sequence analysis of chicken IRF-4.
Mammalian
IRF-4 has been previously cloned and characterized (22, 35, 68,
108). Several of its properties suggest that IRF-4
expression may be important in v-Rel-mediated transformation. IRF-4
is expressed in lymphocytes, the hematopoietic target cells of v-Rel,
and is induced by proliferative stimuli (62, 68). Furthermore, mice deficient in IRF-4, like those deficient in c-Rel, have defects in B-cell proliferation (55, 71).
These similarities, together with the presence of
B sites in the
IRF-4 promoter, suggest that IRF-4 expression may potentially
be regulated by c-Rel and its oncogenic form, v-Rel (68).
To evaluate the role of IRF-4 in v-Rel-mediated transformation, we
isolated the avian IRF-4 homologue. The avian IRF-4 cDNA
is
3,178 nt long (Fig.
1A). The longest ORF encodes a protein
of 445 amino
acids with a predicted molecular mass of 51 kDa.
The start codon of
this ORF, at nt 140 to 142, is located downstream
of an in-frame
termination codon at nt 119 to 121. A second potential
start codon is
located at nt 164 to 166 (Fig.
1B). Both potential
start codons are
also found in mammalian IRF-4 genes (
22,
108).
The 5'
UTR of chicken IRF-4 is short and GC-rich, like the 5'
UTRs of
mammalian IRF-4 homologues (Fig.
1A) (
35,
68). The
1.7-kb 3' UTR of avian IRF-4 is significantly shorter than the
3.5-kb 3' UTRs of mammalian IRF-4 genes (
35,
68).
While chicken
3' UTR sequences are generally divergent from their
mammalian
counterparts, a 46-bp-long conserved region of sequence
homology
was identified (Fig.
1A and C). The chicken 3' UTR sequence
contains
a polyadenylation signal (AATAAA) at nt 3157 to 3162 located
upstream
of the poly(A)
tract.
In addition to the 3,178-nt IRF-4 cDNA, we also identified a
3,070-nt cDNA isoform encoded by an EST clone isolated from a
ConA-activated chicken splenic T-cell library (
106). This
isoform
represents a novel, alternatively spliced form of IRF-4.
The predicted
exon structure of chicken IRF-4, based on the known
exon-intron
structure of mouse and human IRF-4, indicates that the
alternative
form of IRF-4 is missing exon 6 (Fig.
2A) (
35,
68). This variant,
IRF-4

E6, has not been described for mammalian IRF-4;
however,
a different type of alternative splicing has been detected in
mouse and human IRF-4. About 50% of the mammalian IRF-4 clones
contain an additional glutamine residue at the boundary between
the
fourth and fifth exons (
35,
68). Four independently
isolated
clones of chicken IRF-4 did not contain this glutamine
residue,
suggesting that this form may not exist in the chicken.

View larger version (96K):
[in this window]
[in a new window]
|
FIG. 2.
Comparison of predicted amino acid sequence of chicken
IRF-4 with mouse and human IRF-4 and with chicken IRF-8
(chICSBP). (A) Sequence alignment of the chicken (ch), mouse (m), and
human (h) IRF-4 protein sequences. Boundaries of individual exons
of chicken IRF-4 were predicted based on the known exon-intron
structure of the mouse and human IRF-4 genes. This prediction is
supported by the highly conserved exon-intron structure of avian and
mammalian IRF-8 genes (21, 52). Exons are numbered from 2 to 9, and the exon boundaries are indicated by a T sign. The underlined
sequence encoded by exon 6 indicates the amino acids absent in
IRF-4 E6. The codons for glycine 207 and aspartic acid 243 are spliced together in IRF4 E6 mRNA, forming a codon for
aspartic acid. (B) Identical amino acids within predicted functional
domains: N terminus (N), DBD, putative NLS (hatched box),
transactivation domain (TD), exon 6 (E6), IAD, and the C terminus (C).
These functional domains are located in chicken IRF-4 at the
following amino acid positions: N terminus (1 to 15), DBD (16 to 126),
putative NLS (127 to 134), transactivation domain (135 to 206), exon 6 (207 to 242), IAD (241 to 407), and C terminus (408 to 445). The region
between amino acids 198 and 234 of chicken IRF-4 was determined by
the program PEST-FIND to be a poor PEST sequence, with an assigned
score of 3.95 (score ranges from 50 to +50, and only sequences with
a score above +5 are considered likely to act as a PEST domain).
Similar scores were obtained for homologous regions of human and mouse
IRF-4.
|
|
Amino acid sequence analysis confirmed that cloned IRF-4 is the
chicken homologue of mammalian IRF-4. The chicken IRF-4
sequence
is 84.3 and 83.8% identical to human and mouse IRF-4
amino acid
sequences, respectively (Fig.
2A). The identity drops off
significantly
when chicken IRF-4 is compared to chicken, human, and
mouse IRF-8,
with 38.4, 38.6, and 38.4% identity, respectively. Other
vertebrate
IRF family members show even less sequence identity (data
not
shown). The availability of the first nonmammalian IRF-4
enabled
us to compare the evolutionary conservation of the different
functional
regions of IRF-4 (Fig.
2B). The DNA-binding domain (DBD)
and IRF
association domain (IAD), which are not only very similar
between
avian and mammalian IRF-4 but are also shared with other
IRF family
members, are highly conserved. In contrast, the N terminus
and
the middle proline-rich region of IRF-4 show the highest
sequence
variation between avian and mammalian IRF-4. The low
evolutionary
conservation of the middle proline-rich region is in
agreement
with its proposed function as a transactivation domain and a
flexible
connector of DBD and IAD (
14,
79). The remaining
three regions
of IRF-4, the GAKKGAKQ motif, the region encoded by
exon 6, and
the C terminus, are not similar to the corresponding
regions of
other members of the IRF family, but they are highly
conserved
between avian and mammalian IRF-4, suggesting that they
may provide
important functions. The GAKKGAKQ motif, which immediately
follows
the DBD, has an amino acid composition similar to that of a
nuclear
localization sequence (NLS) and resides at the same location as
the NLS of IRF-1 (
96). The C-terminal sequences may be
conserved
because of their ability to regulate the DNA binding of
IRF-4
(
13).
Characterization of IRF-4 protein.
The protein product of
the cloned IRF-4 cDNA was detected by Western analysis, confirming
that the cDNA encodes a protein corresponding in size to the protein
produced by the endogenous IRF-4 gene (Fig.
3). The coding region of IRF-4 was
inserted into a retroviral vector and expressed in CEF cultures, in
which no detectable IRF-4 protein is normally present. This protein
was then compared with endogenous IRF-4 from the chicken C4-1
B-cell line transformed by the S2A3 v-rel oncogene (Fig.
3A). IRF-4 was expressed at comparable levels in both cell types
and was detected as two closely migrating species with molecular
weights corresponding to the theoretical molecular weight of IRF-4.

View larger version (36K):
[in this window]
[in a new window]
|
FIG. 3.
Comparison of chicken IRF-4 and IRF-4 E6
proteins expressed from retroviral vectors in CEFs with endogenously
expressed IRF-4 in chicken B cells. Western blot analysis was
performed using IRF-4 antiserum AI4-6. (A) Two isoforms of
IRF-4. Lysate from control CSV-infected CEFs is shown in lane 1. Two isoforms of IRF-4 detected in whole-cell lysates of CEF
infected with retroviruses expressing IRF-4 (lane 2) comigrate with
two isoforms of IRF-4 from whole-cell lysates of the S2A3
v-rel-transformed splenic B-cell line C4-1 infected with
CSV (lane 3). Whole-cell extracts from 4 × 105 cells
were loaded in each lane. (B) Differential subcellular localization of
the IRF-4 isoforms in CEF cultures. Cytoplasmic (C) and nuclear (N)
lysates from 2 × 105 CEFs infected with CSV (lanes 1 and 2) or exogenously expressing IRF-4 or IRF-4 E6 from retroviral
vectors (lanes 3 to 6) were loaded in each lane. (C) Differential
subcellular localization of the IRF-4 isoforms in bursal cells.
Cytoplasmic (C) and nuclear (N) lysates from normal untreated bursal
cells (lanes 1 and 2) and bursal cells treated with PMA for 5 h
(lanes 3 and 4). Extracts from 2.5 × 106 bursal
lymphocytes were loaded in each lane.
|
|
To further characterize the protein, its subcellular localization was
established. In the cytoplasm of CEFs expressing IRF-4
from a
retroviral vector, a slower-migrating IRF-4 species was
more
abundant than a faster-migrating form, while in the nucleus
the
faster-migrating form was prevalent (Fig.
3B, lanes 3 and
4). The
exogenously expressed IRF-4

E6 protein variant had a similar
subcellular localization as full-length IRF-4 (Fig.
3B, lanes
5 and
6). In bursal lymphocytes, very small amounts of the two
IRF-4
isoforms were found, and most of the IRF-4 protein was located
in
the nucleus as the faster-migrating form. Both IRF-4 cytoplasmic
isoforms dramatically increased in abundance, and the level of
nuclear
IRF-4 was elevated after stimulation with PMA (Fig.
3C,
lanes 3 and
4). The presence of two IRF-4 species in fibroblasts
and lymphoid
cells is most likely the result of posttranslational
modification,
which may function to regulate nucleocytoplasmic
transport. Regulation
of subcellular localization by phosphorylation
has been described for
several other IRF family members (
60,
66). Collectively,
these experiments showed that exogenously
expressed IRF-4 in CEF
cultures has a similar migration pattern
and subcellular distribution
as the endogenous IRF-4 found in
v-Rel-transformed or
PMA-stimulated B
cells.
Expression of IRF-4 in normal and transformed cells.
To
determine whether chicken IRF-4 is expressed principally in
lymphoid cells, as described for its mammalian counterpart, Northern
analysis was performed using total RNA from a variety of organs of
adult chickens, including spleen, bursa, thymus, bone marrow,
peripheral blood, lungs, liver, intestine, gizzard, kidney, gonads,
brain, muscles, heart, and skin (Fig. 4
and data not shown). High expression of chicken IRF-4 mRNA was
detected exclusively in tissues of hematopoietic origin, with the
highest level found in cells of the avian B-cell-specific organ, the
bursa of Fabricius, followed by spleen, peripheral white blood cells, thymus, and bone marrow (Fig. 4A, upper panel). Higher expression was
detected in purified lymphocyte populations than in the intact organ.
Low levels of IRF-4 were also detected in the small intestine and
lungs. Two mRNAs of different size were detected in the small intestine. In addition, Northern blot analysis revealed that the tissue-specific expression of c-rel correlates with that of
IRF-4 (Fig. 4A, lower panel).

View larger version (54K):
[in this window]
[in a new window]
|
FIG. 4.
Expression patterns of chicken IRF-4,
IRF-4 E6, and c-rel mRNA. Expression was
analyzed by Northern blot analysis (panels A and C) and by RT-PCR
(panels B and D). Total RNA (10 µg) was subjected to Northern blot
analysis. The probes used to detect c-rel or
v-rel and IRF-4 mRNA are described in Table 1.
RT-PCR was performed on RNA samples used in Northern blot analysis.
Forty PCR cycles were completed. (A) Expression of IRF-4 and
c-rel mRNA in various tissues from a 1-month-old
chicken. Peripheral white blood cells (WBC) and lymphocyte-enriched
fractions from bursa, thymus, and spleen were obtained by Histopaque
purification as described in Materials and Methods. The intensity of
the rRNA stained with ethidium bromide is shown in the bottom panel
(rRNA). (B) Expression of IRF-4 and IRF-4 E6 in bursal,
splenic, and thymic lymphocytes, peripheral white blood cells, and bone
marrow cells determined by RT-PCR. pREV-IRF-4 E6 and
pREV-IRF-4 plasmids were PCR amplified with the same primers used
for RT-PCR (lanes 6 and 7). (C) Expression of IRF-4 (upper panel),
c-rel mRNA, and retrovirally expressed
v-rel RNA (middle panel) in transformed cell lines as
determined by Northern blotting. RNAs from B-cell lines DT40 and DT95,
T-cell lines MSB-1 and RP-1, myeloblastoid cell line BM-2,
erythroblastoid cell line AEV-1, v-rel-transformed
B-cell line 123/12, T-cell line 160/2, and macrophage-like cell line
123/6T were analyzed. The intensity of the rRNA stained with ethidium
bromide is shown in the bottom panel (rRNA). (D) Expression of
IRF-4 and IRF-4 E6 in DT95, DT40, MSB-1, RP-1, BM-2, AEV-1,
123/12, 160/2, and 123/6T cell lines determined by RT-PCR.
pREV-IRF-4 E6 and pREV-IRF-4 plasmids were PCR amplified with
the same primers as used for RT-PCR (lanes 10 and 11).
|
|
In order to determine the expression of IRF-4

E6, RNA isolated
from bursal, thymic, splenic, and peripheral blood lymphocytes
and from
bone marrow was analyzed by RT-PCR (Fig.
4B). IRF-4

E6
mRNA
was detected at various levels in all of these tissues, with
the
highest expression detected in thymocytes, followed by lymphocytes
from
spleen and peripheral blood. In all tissues, the spliced
form
represented the minor fraction of the total IRF-4
mRNA.
Northern blot analysis of IRF-4 expression in immortalized avian
cell lines demonstrated that its expression is highest in
v-Rel-transformed cell lines of B, T, and non-T, non-B phenotypes
(Fig.
4C, lanes 7 to 9). High expression was also detected in
the Marek's
disease virus-derived T-cell lines MSB-1 and RP-1
and in B-cell lines
DT40 and DT95, derived from ALV-induced B-cell
lymphomas. Low levels of
IRF-4 expression were detected in the
macrophage cell line BM-2
after longer exposure (data not shown).
IRF-4 expression was not
detected by Northern blot analysis in
the AEV-1 cell line. However,
IRF-4 was detected in all cell lines,
including the one transformed
by AEV-1, by RT-PCR (Fig.
4D). IRF-4

E6
was also detected as a
minor component of total IRF-4 mRNA in
all the cell lines. The
highest expression of the spliced form
was found in v-
rel-
and Marek's disease virus-transformed cell
lines.
v-Rel and c-Rel induce expression of IRF-4 in transformed
fibroblasts.
Both v-Rel and c-Rel transform CEFs (1, 26, 45,
59, 72, 74). To define whether IRF-4 may contribute to
v-Rel- and c-Rel-mediated transformation, the steady-state level of
IRF-4 mRNA in normal fibroblasts and transformed fibroblasts
was determined by Northern blot analysis (Fig.
5). Though IRF-4
mRNA was not detected in normal CEFs, IRF-4 was expressed in
both v-Rel- and c-Rel-transformed CEF cultures (Fig. 5A). RT-PCR
revealed that expression of both the full-length and spliced IRF-4
variants was induced in transformed cells. As observed in the lymphoid cell lines, full-length IRF-4 was the predominant form (Fig. 5B, lanes 1 to 3). Although not detected by Northern analysis, a
significant amount of IRF-4 mRNA was detected by RT-PCR in
normal chicken fibroblasts (Fig. 5B, lane 4).

View larger version (23K):
[in this window]
[in a new window]
|
FIG. 5.
v-Rel and c-Rel induce the expression of IRF-4 in
transformed fibroblasts. (A) Expression of IRF-4 mRNA in
uninfected fibroblasts (UN) and fibroblasts either infected with empty
retroviral vector (DS3), transformed by DSv-Rel, infected with empty
retroviral vector RCAS, or transformed by RCASc-Rel. Total RNA (10 µg) was subjected to Northern blot analysis with the probes
described in Table 1. The viral genomic and spliced RNAs in DSv-Rel- or
RCASc-Rel-infected cells shown in the panel labeled Rel were detected
with a c-rel probe. The endogenous c-rel
mRNA was below the threshold of detection at this exposure. The
membrane hybridized with a c-rel probe was exposed to
film for 2 h, while the IRF-4 membrane was exposed for 48 h. The intensity of the rRNA stained with ethidium bromide is shown in
the bottom panel (rRNA). (B) Expression levels of IRF-4 and
IRF-4 E6 mRNA in uninfected fibroblasts (UN) and fibroblasts
transformed by DSv-Rel or transformed by RCASc-Rel were determined by
RT-PCR. Lanes 1 to 3 show the products from these cell types after 35 cycles, while lane 4 shows the product from uninfected fibroblasts
after 40 cycles. The PCR products corresponding to IRF-4 and
IRF-4 E6 are indicated on the right side of the panel. (C)
Western blot analysis of IRF-4 and Rel expression in fibroblasts.
Whole-cell extracts from fibroblasts either infected with empty
retroviral vector DS3, transformed by DSv-Rel, infected with CSV helper
virus, or transformed by REV-TW and from sarcoma-derived fibroblastoid
cell line 26T6 were analyzed. Lane 6 contains a mixture of lysate from
CEFs overexpressing IRF4 from a retroviral vector and lysate from
CSV-infected control CEFs (1:9). Extracts from 3 × 105 to 4 × 105 CEFs and 26TS cells were
loaded per lane, blotted, and stained with anti-IRF-4 AI4-6 serum
(upper panel) or anti-Rel HY87 antibody (lower panel). Positions of the
two IRF-4 bands, a prominent background band (B), v-Rel, and c-Rel
are indicated on the right side. The bands marked with the asterisk and
numbers 1 to 4 in lane 5 are discussed in the text.
|
|
In contrast to normal cells, the IRF-4 protein was detected in
v-Rel- and c-Rel-transformed fibroblasts (Fig.
5C). As in
v-Rel-transformed
lymphoid cell lines, two closely migrating IRF-4
species were
detected in CEFs transformed by v-Rel expressed from
either ALV
(DSv-Rel, lane 2) or REV-based retroviral vectors (REV-TW,
lane
4). By comparing it to the standard shown in lane 6, we estimated
that the amount of IRF-4 in v-Rel-transformed fibroblasts is 20
to
40 times lower than in v-Rel-transformed lymphoid cell lines
or in fibroblasts overexpressing IRF-4 from retroviral vectors.
However, in contrast to cells expressing large quantities of IRF-4,
v-Rel-transformed fibroblasts had a faster-migrating form of IRF-4
localized almost exclusively in the nucleus (data not shown).
Importantly, the IRF-4 protein was detected not only in fibroblasts
transformed in vitro but also in the tumor-derived fibroblastoid
cell
line 26TS (lane 5). This cell line was established from a
solid tumor
induced by c-Rel
gi, a c-Rel mutant with two single
amino
acid substitutions in the middle region of the protein
(
81).
The two proteins detected by staining with antibody
specific to
c-Rel and v-Rel (lane 5, bands 1 and 2) are the full-length
and
a C-terminal deletion mutant of c-Rel
gi mutant.
Retrovirally expressed
c-Rel is known to undergo frequent deletions of
its C terminus
in vivo that increase its tumorigenic potential
(
43). Two additional
proteins (bands 3 and 4) are most
likely degradation products
of these abundantly expressed proteins.
Apparently the high expression
of mutant c-Rel proteins results in a
high induction of IRF-4
expression, as the amount of IRF-4 in
26TS cells approaches almost
one-quarter the amount detected in
v-Rel-transformed lymphoid
cells. In addition to the two IRF-4
species, a third protein is
seen on the blot of 26TS cell lysates
(marked by an asterisk),
the identity of which is unknown. The
induction of IRF-4 expression
in Rel-transformed fibroblast
cultures and the presence of IRF-4
protein in the fibroblastoid
tumor cells suggest that IRF-4 may
contribute to v-Rel- and
c-Rel-mediated transformation of fibroblasts
and that IRF-4 may
also be physiologically regulated by c-Rel
in
fibroblasts.
To evaluate whether the induction of expression of IRF-4 is a
general characteristic of transformed fibroblasts, the expression
of
IRF-4 in primary fibroblasts transformed by several oncogenes
and
in two sarcoma cell lines was analyzed (data not shown). In
contrast to
v-
rel-transformed fibroblasts, fibroblasts transformed
by
v-
src, v-
ros, activated c-Ha-
ras,
v-
ski, v-
qin, v-
jun, and
v-
PI-3
kinase and QT6 and 1757 sarcoma cell lines did not express
IRF-4 mRNA, indicating that the induction of IRF-4 is not a
general
feature of fibroblast
transformation.
IRF-4 transforms primary chicken fibroblasts and participates
in transformation with v-Rel.
Preliminary experiments showed that
fibroblasts which express IRF-4 or IRF-4
E6 from retroviral
vectors become morphologically transformed. In order to characterize
these transformed cells and analyze the contribution of IRF-4 and
IRF-4
E6 to v-Rel-mediated transformation, CEF cultures were
infected with retroviruses expressing v-Rel, IRF-4, or
IRF-4
E6 or coinfected by viruses expressing v-Rel and IRF-4
or v-Rel and IRF-4
E6. The infected cells expressed high levels
of the exogenously expressed proteins (Fig.
6A). Both v-Rel- and
IRF-4-overexpressing cells became morphologically transformed 1 week after viral infection. The shape and orientation of cells expressing v-Rel were, however, distinct from those of cells expressing IRF-4 (Fig. 6B). v-Rel-transformed fibroblasts were rounded, with irregular edges, and disorganized. The size of these cells varied greatly, and the presence of giant cells was observed.
IRF-4-transformed cells retained a more regular growth pattern and
did not vary in size. At low density, they assumed a short cylindrical
shape which at confluence changed to small, rounded, very densely
packed cells. Cells overexpressing both genes had a morphology which was intermediate between those of v-Rel- and IRF-4-transformed cells: the cells had the disorganized growth pattern of
v-Rel-transformed cells and, like IRF-4-transformed cells, grew to
high density. Control cultures expressing the helper virus CSV or empty
vector were morphologically indistinguishable from uninfected cells
(data not shown). Cells expressing IRF-4
E6 or coexpressing v-Rel
and IRF-4
E6 were morphologically similar to cells expressing
IRF-4 or v-Rel and IRF-4, respectively. The morphological
changes in these cells were, however, less pronounced than in those
expressing full-length IRF-4 (data not shown).

View larger version (105K):
[in this window]
[in a new window]
|
FIG. 6.
Transformation of chicken fibroblasts by v-Rel and
IRF-4. CEFs were infected by retroviruses expressing v-Rel,
IRF-4, or IRF-4 E6 or coinfected by v-Rel-expressing viruses
with either IRF-4- or IRF-4 E6-expressing viruses at a
multiplicity of infection of 3. Control cells were left uninfected or
infected with CSV and DS3 empty-vector retroviruses. The morphology of
these cells, their ability to form soft agar colonies, and the level of
v-Rel and retrovirally expressed IRF-4 or IRF-4 E6 expressed
in them were analyzed between 2 and 3 weeks after infection. (A) Equal
protein levels of exogenously expressed IRF-4, IRF-4 E6, and
v-Rel in singly and doubly infected cultures. Whole-cell extracts from
2 × 105 cells from the cultures shown below were
blotted and stained with anti-IRF-4 AI4-6 serum (left panel) or
anti-Rel HY87 antibody (right panel). Positions of IRF-4 and Rel
proteins are indicated on the right side of each panel. (B)
Phase-contrast microphotography of low-density (LD) and high-density
(HD) cultures. Original photographs were taken at 100× magnification;
the printed images are decreased to 70% of the original. Since all
three control groups had identical morphology, only the results for
CSV-infected control cells are shown. The morphology of cells
transformed by IRF-4 E6-infected or v-Rel- and
IRF-4 E6-infected fibroblasts was less pronounced but otherwise
similar to IRF-4- or v-Rel- and IRF-4-transformed cells,
respectively. The growth of cells transformed by v-Rel, IRF-4, or
v-Rel and IRF-4 in soft agar is shown in the bottom row of panels.
Since none of the three control groups form colonies in soft agar, only
the results for CSV-infected control cells are shown. CEF cultures
infected with these viruses were plated in soft agar 4 weeks after
infection, and the growth of colonies was scored 3 weeks after plating.
Original photographs were taken at 40× magnification; the printed
images are decreased to 56% of the original size.
|
|
The proliferation rate, saturation density, and ability to form soft
agar colonies of cells infected with retroviruses expressing
v-Rel,
IRF-4, or IRF-4

E6 or coinfected by these viruses was
analyzed
30 to 40 days after infection (Table
2). These transformation
characteristics
were compared with parameters determined for uninfected
and DS3- and
CSV-infected control cells. v-Rel-transformed cells
did not proliferate
more rapidly than control cells and grew to
the same saturation density
as control cells. However, in contrast
to control cells,
v-Rel-transformed cells formed colonies in soft
agar. Cell cultures
expressing IRF-4 or IRF-4

E6 proliferated
approximately twice
as rapidly as control cells. These cultures
also reached a saturation
density approximately two to three times
higher than that of
v-Rel-expressing and control cells. IRF-4
and IRF-4

E6, like
v-Rel, induced the limited growth of colonies
in soft agar. v-Rel and
IRF-4 functioned synergistically to increase
the proliferation
rate, saturation density, and colony formation
ability of the
fibroblasts. Cells coexpressing v-Rel and either
IRF-4 or
IRF-4

E6 proliferated about four times more rapidly than
v-Rel-infected cells and two times more rapidly than IRF-4- or
IRF-4

E6-infected cells. Fibroblasts coexpressing v-Rel and
IRF-4
(but not IRF-4

E6) grew to a saturation density four
times higher
than that of v-Rel-expressing cells and stopped growing
when they
reached 30 × 10
6 cells on
60-mm-diameter dishes (1.4 × 10
6/cm
2). The coexpression
of IRF-4 and v-Rel also significantly enhanced
soft agar colony
formation relative to fibroblast cells expressing
either v-Rel or
IRF-4. These cells produced about 12 times more
colonies, which in
turn grew to a diameter about three times greater
than that of
colonies formed by cells expressing v-Rel or IRF-4
alone (Table
2,
Fig.
6B).
View this table:
[in this window]
[in a new window]
|
TABLE 2.
Characterization of CEF cultures transformed by v-Rel,
IRF-4, IRF-4 E6, v-Rel plus IRF-4, and v-Rel plus
IRF-4 E6a
|
|
The life span of v-Rel- and IRF-4-transformed cells was also
analyzed by monitoring the number of cell doublings in cell culture
(Fig.
7). Cells coexpressing v-Rel and
IRF-4 or v-Rel and IRF-4

E6
began to proliferate more rapidly
than uninfected cultures after
1 week and continued to do so until 60 days after infection. Two
weeks after infection, cells expressing
IRF-4 or IRF-4

E6 also
began to proliferate more rapidly than
control cultures, while
v-Rel-expressing cultures entered crisis at
approximately 10 days,
during which time they grew more slowly than
control cells. When
v-Rel-expressing cultures overcame this crisis,
they began to
proliferate at the same rate as uninfected cells or
control cells
infected with the empty vector. Finally, cells
overexpressing
both v-Rel and IRF-4 or IRF-4

E6 reached two
times the number
of generations of control cells or v-Rel-transformed
cells (Table
2). Cells overexpressing IRF-4 or IRF-4

E6 alone
doubled less
frequently than these cells but still doubled
approximately 30
more times than control or v-Rel-expressing cells.
IRF-4 therefore
cooperates synergistically with v-Rel in the
transformation of
CEFs.

View larger version (21K):
[in this window]
[in a new window]
|
FIG. 7.
Growth curves of cells expressing IRF-4,
IRF-4 E6, v-Rel, and IRF-4 or IRF-4 E6, with v-Rel
showing the cumulative increase in cell generations with time in
culture. CEFs were infected with retroviruses expressing v-Rel ( ),
IRF-4 ( ), or IRF-4 E6 ( ) or coinfected with
retroviruses expressing v-Rel and IRF-4 ( ) or v-Rel and
IRF-4 E6 (×) at a multiplicity of infection of 3. Control cells
were infected with empty vector retroviruses ( ) or left uninfected.
Uninfected fibroblasts had the same number of generations as
fibroblasts infected by empty vector (data not shown). Each culture was
split 1:8 when it reached confluence. This experiment was repeated
twice with similar results.
|
|
Antisense IRF-4 RNA decreases soft agar colony formation and
proliferation of v-Rel-transformed fibroblasts.
To determine if
the induction of endogenous levels of IRF-4 in v-Rel-expressing
fibroblasts contributes to their transformation, we used antisense RNA
technology as a complementary approach to the coexpression studies
described above. Western blot analysis of C4-1 cells demonstrated that
the expression of IRF-4 in the antisense orientation reduced the
levels of IRF-4 protein in v-Rel-transformed cells to less than
50% of wild-type levels (Fig. 8).
v-Rel-transformed fibroblasts and lymphoid cells were infected with
retroviruses expressing the IRF-4 gene in the antisense
orientation. Both types of cells began to grow significantly more
slowly (three to six times) than control cells infected with the CSV
helper virus (Table 3). Interestingly,
the growth of normal fibroblasts was also inhibited by the expression
of the antisense IRF-4 construct. The ability of v-Rel-transformed
fibroblasts expressing antisense IRF-4 to proliferate and to form
colonies in soft agar was then determined (Table 3). In contrast to
v-Rel-transformed fibroblasts, cells coexpressing v-Rel and antisense
IRF-4 did not form colonies in soft agar. Collectively, the
inability of v-Rel-transformed cells expressing antisense IRF-4 to
form colonies in soft agar, the efficient transformation of fibroblasts
by IRF-4 alone, and the cooperation of v-Rel and IRF-4 in
fibroblast transformation suggest that increased levels of IRF-4 in
v-Rel-transformed fibroblasts contribute to their transformation.

View larger version (49K):
[in this window]
[in a new window]
|
FIG. 8.
Expression of an antisense IRF-4 construct reduces
IRF-4 expression in v-Rel-transformed cells. The S2A3
v-rel lymphoid cell line C4-1 was infected with
REV-anti-IRF-4 (anti-IRF-4) or with CSV helper (control).
Whole-cell extracts were prepared 48 h after infection and
analyzed by Western blot using AI4-6 (anti-IRF-4) serum and HY87
(anti-Rel) antibody. The extracts from 105 cells were
loaded in each lane. Positions of IRF-4 and Rel proteins are
indicated on the right side of each panel.
|
|
IRF-4 represses v-Rel-induced expression of the negative cell
proliferation regulator IFN1.
v-Rel-transformed fibroblasts do not
proliferate more rapidly than control cells and enter crisis at 2 weeks
after infection, at which time their proliferation rate decreases
relative to control cells (Table 2). This is perplexing because
v-Rel-transformed fibroblasts not only have increased levels of
IRF-4 but also constitutively express elevated levels of c-Jun and
c-Fos, which are known to induce cell proliferation (58).
The expression of IRF-4 in v-Rel-transformed cells rescues
v-Rel-transformed cells from their proliferation defect (Table 2).
Since Rel/NF-
B, Jun/ATF-2, and IRF family members are known to
cooperatively regulate the expression of type I IFNs, we determined
whether v-Rel induces IFN, which in turn suppresses the proliferation
of v-Rel-transformed cells (107). The expression of avian
IFN1 mRNA in v-Rel-transformed cells was strongly increased
relative to that in control cells (Fig.
9A, lanes 1 and 4).

View larger version (61K):
[in this window]
[in a new window]
|
FIG. 9.
Modulation of the expression of genes of the IFN
transduction pathway by IRF-4 and IRF-4 E6 in
v-Rel-transformed fibroblasts. (A) The expression of IFN1 and the
control gene GAPDH as determined by RT-PCR. Total RNA was prepared from
the cultures described in the legend to Fig. 6. Products of PCR
amplification from pcDNAchIFN1 (Table 1) using the same primers as in
RT-PCR are shown (lane 7). Because IFN1 is an intronless gene, RNAs for
cDNA synthesis were first treated with DNase I as described in
Materials and Methods. PCR with pretreated RNA as a substrate confirmed
that no detectable IFN1 DNA was present in the RNA samples (data not
shown). (B) CEF cultures were infected with empty vector viruses DS3
and CSV for 1 week to induce resistance of CEF to subsequent viral
infection. Cells were seeded to 24-well plates (104 cells
per well), and medium was replaced with 0.5 ml of culture supernatant
from v-Rel- or v-Rel- and IRF-4-transformed fibroblasts after 1 day. The supernatant fluids from DS3 virus-expressing CEFs were used as
a control. The supernatant fluids from v-Rel-transformed and control
cells were also incubated with monoclonal antibody 8A9 against IFN1
(purified immunoglobulin diluted 1:1,400) for 2 h on ice before
application to CEF cultures. The number of cells in each culture was
determined 2 days after exposure to the culture medium. The mean and
standard errors (error bars) for three to six independent experiments
are shown. (C) Expression of IFNaR1, IFNaR2, JAK1, STAT1, and OAS genes
was determined by Northern blot analysis. RNA was prepared from the
cultures shown in Fig. 6.
|
|
Mammalian IFNs have antiproliferative effects on certain cell types,
but the effect of avian IFNs on cell growth has not been
reported
(
49). To determine whether IFN1 exerts an
antiproliferative
effect on avian fibroblasts, recombinant IFN1 was
produced in
COS-1 cells. Fibroblasts treated with recombinant IFN1
proliferated
half as fast as control cells, suggesting that the
induction of
IFN1 by v-Rel may be responsible for the failure of these
transformed
cells to proliferate more rapidly than the control cells
(data
not shown). Therefore, the effect of IRF-4 on the expression
of
IFN1 in v-Rel-transformed and control fibroblasts was determined
(Fig.
9A). IFN1 expression was repressed in control and in
v-Rel-transformed
cells by the expression of IRF-4 (and to a lesser
degree by IRF-4

E6).
Therefore, the increased levels of IRF-4
in v-Rel-transformed
cells may partially eliminate the negative effects
of IFN1 on
cell proliferation and permit v-Rel-transformed cells to
proliferate
at rates equivalent to control cells. To test this
hypothesis
directly, culture fluids from v-Rel-transformed cells, cells
transformed
by v-Rel/IRF-4, and control cells were applied to CEF
cultures,
and their proliferation rate was evaluated (Fig.
9B).
Supernatant
fluids from v-Rel-transformed cells contained an
inhibitor which
strongly interfered with the proliferation of
normal fibroblasts.
This antiproliferative activity was partially
reduced by preincubation
with anti-IFN1 antibody. Cells exposed to
supernatant fluids obtained
from v-Rel/IRF-4-transformed cells
proliferated significantly
better than those exposed to culture fluids
from v-Rel-transformed
cells. These results indicate that
v-Rel-transformed cells produce
IFN1, which strongly inhibits cell
proliferation, and that IRF-4
expression decreases the production
of this
inhibitor.
IRF-4 modulates expression of genes involved in IFN
transduction pathway in v-Rel-transformed fibroblasts.
To
determine whether the induction of IFN1 expression in v-Rel-transformed
cells is coordinated with the expression of other components of the IFN
pathway, the levels of mRNA encoding the IFN receptor (IFNaR1 and
IFNaR2), the STAT1 transcription factor and its regulatory kinase,
JAK1, and the IFN target gene OAS were analyzed (Fig. 9C, lanes 1, 2, and 5). The expression of all of these genes was elevated, indicating
that the type I IFN signal transduction pathway is activated in
v-Rel-transformed fibroblasts. In contrast, the expression of IFNaR1
and JAK1 was decreased in cells expressing IRF-4 alone, while the
expression of STAT1 and OAS was increased in these cells (Fig. 9C, lane
3). The possibility that IRF-4 expression may alter the expression
of these genes in v-Rel-transformed cells was explored (Fig. 9C, lanes
1 to 4, 6, and 7). As with IFN1, the expression of IFNaR1 and -2 and
JAK1 was downregulated in cells coexpressing v-Rel and IRF-4s
relative to cells expressing v-Rel alone. While the expression of STAT1 and OAS was also decreased, significant levels of OAS mRNA were still present in cells expressing both v-Rel and IRF-4.
Collectively, these results suggest that the expression of IRF-4,
and to a lesser extent IRF-4
E6, not only influences the
expression of IFN1 but also modulates the expression of other genes in
the IFN transduction pathway, likely decreasing the sensitivity of
cells to the antiproliferative effects of IFN1. IRF-4, however,
does not appear to be a general repressor of genes of the IFN
transduction pathway, but is rather a modulator of their relative
expression levels.
 |
DISCUSSION |
In this report we described the molecular cloning of chicken
IRF-4 and the distribution of IRF-4 expression in tissues and cell lines and identified a novel splice variant of this gene. We
further demonstrated that IRF-4 transforms primary fibroblast cells
and that its expression is induced in fibroblasts by v-Rel and c-Rel
and established a role for IRF-4 in the transformation of
fibroblasts by v-Rel.
Alternative splice variant of IRF-4.
A differentially
spliced variant of IRF-4 mRNA (IRF-4
E6) was isolated
that does not contain exon 6 and consequently has a deletion of 36 amino acids immediately preceding the IAD. The amino acid sequence
encoded by exon 6 is highly conserved between mammalian and avian
IRF-4 family members, suggesting that this region may be
functionally important. This region was described earlier as a
potential PEST sequence (22). PEST sequences, which are
rich in proline, glutamic acid, serine, and threonine amino acids, have
been identified as destabilizing motifs that target proteins for rapid
degradation (92). However, analysis of the IRF-4
sequence using the PEST motif prediction algorithm suggests that it is
unlikely that this sequence serves as a PEST sequence (see legend to
Fig. 2B). While the IRF-4
E6 protein could be overexpressed to
slightly higher steady-state levels than IRF-4 in fibroblasts, this
difference does not suggest a dramatically different half-life. Previously, a 96-amino-acid-long domain in mouse IRF-4 was
identified that appears to mask IRF-4 transactivation activity
(79). This domain includes all 36 residues encoded by exon
6, suggesting that the exon 6-encoded region may serve as a regulator
of transactivation function. Various levels of IRF-4
E6 mRNA
were detected by RT-PCR analysis in several lymphoid and hematopoietic
tissues, albeit at lower abundance than full-length IRF-4. The
levels of IRF-4
E6 varied in different tissues, with the highest
levels detected in thymus cells. Collectively, these results suggest
that IRF-4
E6 is differentially regulated and has overlapping but
distinct functions compared with full-length IRF-4. Interestingly,
a splice variant of human IRF-7, IRF-7B, was described that is lacking
29 amino acids encoding a region corresponding to exon 6 of IRF-4
(112). Since IRF-7 is not closely related to IRF-4, it
is likely that alternative splicing of the region between the
transactivation domain and IAD is used by additional members
of the IRF family.
IRF-4 transforms primary fibroblast cells.
Several reports
suggested that IRF-4 may function as an oncogene. IRF-4 was
found to be translocated next to the immunoglobulin heavy-chain locus
in 20% of multiple myeloma cell lines, and IRF-4 overexpression
induced the formation of soft agar colonies in the permanent
fibroblastoid cell line Rat-1 (47, 110). Furthermore, it
was suggested that IRF-4 plays an important role in adult T-cell leukemia (108). Other reports, however, failed to show the
ability of IRF-4 to induce leukemogenesis (95). The
results presented in this article show that IRF-4 functions as a
very potent oncogene in fibroblasts. The expression of IRF-4 in
primary fibroblasts increases their saturation density and permits them
to form colonies in soft agar. Moreover, our results demonstrated new
characteristics associated with IRF-4 transformation: dramatic
alteration of cell morphology, decrease of the doubling time to half
that of normal fibroblasts, and significant increases in life span.
The fact that IRF-4 is involved in human oncogenesis is largely
accepted, but how IRF-4 acts as an oncogene has not been explored.
Low but significant levels of IFN1 mRNA, as well as mRNA for
several
components of the IFN signaling pathway, have been detected in
our experiments in normal fibroblasts. It is possible that IRF-4
may, at least partly, regulate fibroblast proliferation by modulating
expression of these genes. Our hypothesis is also consistent with
the
observation that overexpression of antisense IRF-4 reduces
the
proliferation rate of normal fibroblasts. Interestingly, the
recent
report of the isolation of a third viral IRF, vIRF-3, from
human
herpesvirus 8 (HHV-8) suggested a similar mechanism (
65).
HHV-8 is the etiological agent of Kaposi's sarcoma and also plays
an
important role in the pathogenesis of AIDS-associated body
cavity-based
lymphoma. vIRF-3, which is most homologous to IRF-4,
has the
ability to repress transactivation of the IFNA (IFN-

)
gene normally
caused by virus-mediated activation of IRF-3- and
IRF-7.
v-Rel- and c-Rel-induced expression of IRF-4 in fibroblasts
contributes to cell transformation.
The increased expression of
IRF-4 found in v-Rel- and c-Rel-transformed fibroblasts suggests
that IRF-4 is under the control of Rel transcription factors in
CEFs. This is supported by a report by Grumont and Gerondakis,
published while this study was in progress, which demonstrated that
IRF-4 is transcriptionally regulated by c-Rel in murine B
lymphocytes via
B sites present in the IRF-4 promoter
(37). Therefore, it seems likely that IRF-4 is also a
direct transcriptional target of v-Rel and c-Rel in chicken fibroblasts. The expression of about a dozen genes has been found to be
changed in v-Rel-transformed cells (32, 42). However, only
a few of these genes were connected with the transformation phenotype
of cells. The AP-1 family of transcription factors and the chemokine
mip-1
have been shown to play a functional role in
v-Rel-mediated transformation of fibroblasts (58, 87). The
ability of IRF-4 to transform fibroblasts suggested that an increased level of IRF-4 may also contribute to the transformed phenotype of these cells. To test this hypothesis, we performed experiments in which the level of IRF-4 in v-Rel-expressing
fibroblasts was increased or decreased. Coexpression of v-Rel and
IRF-4 synergistically increased transformation of fibroblasts, and
expression of antisense IRF-4 RNA in v-Rel-transformed fibroblasts
prevented the formation of soft agar colonies and reduced the
proliferation of these cells. These results establish that IRF-4
contributes to transformation of fibroblasts by v-Rel.
v-Rel induces expression of genes with antiviral and
antiproliferative functions in fibroblasts.
The expression of
v-Rel results in the development of a cell type-specific cytopathic
effect (81, 100). In most instances, v-Rel-expressing
embryonic fibroblasts, despite their transformed morphology and ability
to grow in soft agar, do not proliferate more rapidly than control
cells (26, 74). REV-T-transformed fibroblast cultures
produce less virus over time, suggesting that there may be a selective
pressure against fibroblasts expressing high levels of v-Rel
(12). Our studies provide a possible explanation for these
observations. The expression of IFN1, which has an antiproliferative effect, is induced in v-Rel-transformed fibroblasts. Simultaneously with the expression of IFN1, the expression of IFNaR1, IFNaR2, STAT1,
and JAK1 is elevated in v-Rel-transformed cells. The induction of
expression of these genes of the IFN transduction pathway suggests that
not only is the level of IFN1 increased, but the sensitivity of CEF
cultures to its action is also increased. As a result, the increased
expression of the IFN target gene OAS was also detected in
v-Rel-transformed cells. The expression of IFN-induced genes has been
shown in many instances to correlate with decreased cell proliferation
(9).
v-Rel likely interacts directly with the promoters of at least some
genes of the IFN/IRF signal transduction cascade. IFN1
itself may be a
v-Rel target gene. It has been shown that the
Rel/NF-

B family
members cooperate with IRF-3, IRF-7, and ATF-2/Jun
transcription
factors in regulation of the mammalian IFN-

promoter
(
107). The lack of information concerning the regulation
of the
IFN type I receptors, STAT1, and JAK1 expression does not permit
speculation about how v-Rel alters their
expression.
IRF-4 modulates v-Rel-induced expression of members of the IFN
signal transduction pathway.
Mammalian IRF-4 was suggested to
be a repressor of IFN-induced gene expression (37, 94).
Our results demonstrate that avian IRF-4 is also able to interfere
with the induction of expression of IFN1 and several other components
of IFN signaling in v-Rel-transformed cells. The downregulation of some
components of the IFN signaling pathway by IRF-4 correlates with an
increased transformation of fibroblasts coexpressing v-Rel and
IRF-4, suggesting that alterations of the IFN pathway by IRF-4
may contribute to fibroblast transformation by v-Rel. However, we also
found that IRF-4 induces the expression of some members of the IFN
signal transduction pathway (STAT1 and OAS) in CEFs. It seems that
IRF-4 acts as a modulator rather than a general repressor of IFN
signaling, inhibiting certain genes while stimulating others. The final
outcome of IFN signaling may depend on the absolute levels of IRF-4
activity in the cell as well as the relative ratio of the IRF-4 to
Rel/NF-
B. Finally, we cannot exclude the possibility that some of
the inhibitory effect of IRF-4 on the IFN signaling pathway in
v-Rel-transformed cells may be the result of a direct influence of
IRF-4 on the activity of v-Rel.
In summary, the increased expression of IFN1 and other genes of the IFN
pathway in v-Rel-transformed cells suggests that the
antiviral program
can be switched on in fibroblast cells by Rel/NF-

B
family members.
This is in agreement with the crucial role of
Rel/NF-

B proteins in
cellular antiviral responses (
31,
73).
In contrast, the
induction of IRF-4 expression by Rel/NF-

B members
elicits a
highly proliferative response (
24,
38). The induction
of
IRF-4 modulates the v-Rel-induced IFN transduction pathway
and
gives cells a proliferative advantage. Our results suggest
that two
cell types transformed by v-Rel, lymphoid cells and fibroblasts,
differ
in the basal and v-Rel-inducible levels of IRF-4. IRF-4
levels
are significantly higher in lymphoid cells than in fibroblasts;
therefore, the ratio of IRF-4 to v-Rel in v-Rel-transformed
lymphoid
cells is higher than in v-Rel-transformed fibroblasts. This
difference
may explain why, in contrast to fibroblasts,
v-Rel-transformed
lymphoid cells proliferate better and can be
immortalized. More
generally, the difference in the level of both
constitutive and
Rel/NF-

B-inducible expression of IRF-4 in these
types of cells
may reflect the way fibroblasts and lymphoid cells
respond to
viral infection. The fibroblasts stop proliferation and are
converted
to antigen-presenting cells, while lymphoid cells actively
proliferate
to amplify cells which can specifically recognize and
eliminate
virus and virus-infected
cells.
 |
ACKNOWLEDGMENTS |
We are grateful to many colleagues for providing chicken cDNA
clones as well as clones of chicken oncogenes in retroviral vectors. We
especially thank Joan Burnside and Robin Morgan (University of
Delaware) for cDNA clones pat.pk0027.c10.f, pat.pk0067.e6.f, and
ptr1c.pk002.b9, which were isolated as a part of the University of
Delaware chicken EST project. We thank Thomas Gilmore (Boston University) for c-rel, Georges Lutfalla (CNRS, France)
for IFNaR1 and IFNaR2, Christine Sick and Peter Staeheli
(Universität Freiburg, Germany) for IFN1 and for monoclonal
antibody specific to IFN1, Martin Zenke (Max-Delbrück-Center,
Germany) for JAK1, Stephen H. Hughes (National Cancer Institute) for
tfch-ras and v-ski, Peter K. Vogt (The
Scripps Research Institute) for v-p3k,
v-qin, and v-jun, and Lu-Hai Wang (Mount
Sinai School of Medicine, New York) for v-ros. We thank
Andrew Liss and Cullen Pendleton for careful reading of the manuscript
and helpful comments. In addition, we are grateful to William Bargmann
for providing DSv-Rel-transformed SPAFAS fibroblasts.
This work was supported by the Council for Tobacco Research 4163 and
Public Health Service grant CA33192 from the National Cancer Institute.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Section of
Molecular Genetics and Microbiology, The University of Texas at Austin, Austin, TX 78712-1095. Phone: (512) 471-5525. Fax: (512) 471-2130. E-mail: bose{at}mail.utexas.edu.
 |
REFERENCES |
| 1.
|
Abbadie, C.,
N. Kabrun,
F. Bouali,
J. Smardova,
D. Stehelin,
B. Vandenbunder, and P. J. Enrietto.
1993.
High levels of c-rel expression are associated with programmed cell death in the developing avian embryo and in bone marrow cells in vitro.
Cell
75:899-912[CrossRef][Medline].
|
| 2.
|
Abdrakhmanov, I.,
D. Lodygin,
P. Geroth,
H. Arakawa,
A. Law,
J. Plachy,
B. Korn, and J. M. Buerstedde.
2000.
A large database of chicken bursal ESTs as a resource for the analysis of vertebrate function.
Genome Res.
10:2062-2069[Abstract/Free Full Text].
|
| 3.
|
Akiyama, Y., and S. Kato.
1974.
Two cell lines from lymphomas of Marek's disease.
Biken J.
17:105-116[Medline].
|
| 4.
|
Altschul, S. F.,
W. Gish,
W. Miller,
E. W. Myers, and D. J. Lipman.
1990.
Basic local alignment search tool.
J. Mol. Biol.
215:403-410[CrossRef][Medline].
|
| 5.
|
Altschul, S. F.,
T. L. Madden,
A. A. Schaffer,
J. Zhang,
Z. Zhang,
W. Miller, and D. J. Lipman.
1997.
Gapped BLAST and PSI-BLAST: a new generation of protein database search programs.
Nucleic Acids Res.
25:3389-3402[Abstract/Free Full Text].
|
| 6.
|
Baba, T. W.,
B. P. Giroir, and E. H. Humphries.
1985.
Cell lines derived from avian lymphomas exhibit two distinct phenotypes.
Virology
144:139-151[CrossRef][Medline].
|
| 7.
|
Baeuerle, P. A.
1991.
The inducible transcription activator NF- B: regulation by distinct protein subunits.
Biochim. Biophys. Acta
1072:63-80[Medline].
|
| 8.
|
Barkett, M., and T. D. Gilmore.
1999.
Control of apoptosis by Rel/NF- B transcription factors.
Oncogene
18:6910-6924[CrossRef][Medline].
|
| 9.
|
Baron, S.,
S. K. Tyring,
W. R. Fleischmann, Jr.,
D. H. Coppenhaver,
D. W. Niesel,
G. R. Klimpel,
G. J. Stanton, and T. K. Hughes.
1991.
The interferons. Mechanisms of action and clinical applications.
JAMA
266:1375-1383[Abstract/Free Full Text].
|
| 10.
|
Bartunek, P.,
N. P. Koritschoner,
D. Brett, and M. Zenke.
1999.
Molecular cloning, expression and evolutionary analysis of the avian tyrosine kinase JAK1.
Gene
230:129-136[CrossRef][Medline].
|
| 11.
|
Bos, T. J.,
F. S. Monteclaro,
F. Mitsunobu,
A. R. Ball, Jr.,
C. H. Chang,
T. Nishimura, and P. K. Vogt.
1990.
Efficient transformation of chicken embryo fibroblasts by c-Jun requires structural modification in coding and noncoding sequences.
Genes Dev.
4:1677-1687[Abstract/Free Full Text].
|
| 12.
|
Bose, H. R., Jr., and A. S. Levine.
1967.
Replication of the reticuloendotheliosis virus (strain T) in chicken embryo cell culture.
J. Virol.
1:1117-1121[Abstract/Free Full Text].
|
| 13.
|
Brass, A. L.,
E. Kehrli,
C. F. Eisenbeis,
U. Storb, and H. Singh.
1996.
Pip, a lymphoid-restricted IRF, contains a regulatory domain that is important for autoinhibition and ternary complex formation with the Ets factor PU.1.
Genes Dev.
10:2335-2347[Abstract/Free Full Text].
|
| 14.
|
Brass, A. L.,
A. Q. Zhu, and H. Singh.
1999.
Assembly requirements of PU.1-Pip (IRF-4) activator complexes: inhibiting function in vivo using fused dimers.
EMBO J.
18:977-991[CrossRef][Medline].
|
| 15.
|
Bushdid, P. B.,
D. M. Brantley,
F. E. Yull,
G. L. Blauerer,
L. H. Hoffman,
L. Nisswander, and L. D. Kerr.
1998.
Inhibition of NF- B activity results in disruption of the apical ectodermal ridge and aberrant limb morphogenesis.
Nature
392:615-618[CrossRef][Medline].
|
| 16.
|
Capobianco, A. J.,
D. L. Simmons, and T. D. Gilmore.
1990.
Cloning and expression of a chicken c-rel cDNA: unlike p59v-rel, p68c-rel is a cytoplasmic protein in chicken embryonic fibroblasts.
Oncogene
5:257-265[Medline].
|
| 17.
|
Chang, H. W.,
M. Aoki,
D. Fruman,
K. R. Auger,
A. Bellacosa,
P. N. Tsichlis,
L. C. Cantley,
T. M. Roberts, and P. K. Vogt.
1997.
Transformation of chicken cells by the gene encoding the catalytic subunit of PI 3-kinase.
Science
276:1848-1850[Abstract/Free Full Text].
|
| 18.
|
Chang, H. W.,
J. Li, and P. K. Vogt.
1996.
Domains of the qin protein required for oncogenic transformation.
Oncogene
13:441-444[Medline].
|
| 19.
|
Colmenares, C.,
P. Sutrave,
S. H. Hughes, and E. Stavnezer.
1991.
Activation of the c-ski oncogene by overexpression.
J. Virol.
65:4929-4935[Abstract/Free Full Text].
|
| 20.
|
DeLorbe, W. J.,
P. A. Luciw,
H. M. Goodman,
H. E. Varmus, and J. M. Bishop.
1980.
Molecular cloning and characterization of avian sarcoma virus circular DNA molecules.
J. Virol.
36:50-61[Abstract/Free Full Text].
|
| 21.
|
Dosch, E.,
B. Zöller,
I. Redmann-Müller,
I. Nanda,
M. Schmid,
A. Viciano-Gofferge, and C. Jungwirth.
1998.
The genomic structure of the chicken ICSBP gene and its transcriptional regulation by chicken interferon.
Gene
210:265-275[CrossRef][Medline].
|
| 22.
|
Eisenbeis, C. F.,
H. Singh, and U. Storb.
1995.
Pip, a novel IRF family member, is a lymphoid-specific, PU.1-dependent transcriptional activator.
Genes Dev.
9:1377-1387[Abstract/Free Full Text].
|
| 23.
|
Filardo, E. J.,
M. F. Lee, and E. H. Humphries.
1994.
Structural genes, not the LTRs, are the primary determinants of reticuloendotheliosis virus A-induced runting and bursal atrophy.
Virology
202:116-128[CrossRef][Medline].
|
| 24.
|
Fini, M. E.
1999.
Keratocyte and fibroblast phenotypes in the repairing cornea.
Prog. Retin. Eye Res.
18:529-551[CrossRef][Medline].
|
| 25.
|
Foo, S. Y., and G. P. Nolan.
1999.
NF- B to the rescue: RELs, apoptosis and cellular transformation.
Trends Genet.
15:229-235[CrossRef][Medline].
|
| 26.
|
Franklin, R. B.,
C.-Y. Kang,
K. M.-M. Wan, and J. H. R. Bose.
1977.
Transformation of chick embryo fibroblasts by reticuloendotheliosis virus.
Virology
83:313-321[CrossRef][Medline].
|
| 27.
|
Fujii, Y.,
T. Shimizu,
M. Kusumoto,
Y. Kyogoku,
T. Taniguchi, and T. Hakoshima.
1999.
Crystal structure of an IRF-DNA complex reveals novel DNA recognition and cooperative binding to a tandem repeat of core sequences.
EMBO J.
18:5028-5041[CrossRef][Medline].
|
| 28.
|
Gao, S. J.,
C. Boshoff,
S. Jayachandra,
R. A. Weiss,
Y. Chang, and P. S. Moore.
1997.
KSHV ORF K9 (vIRF) is an oncogene which inhibits the interferon signaling pathway.
Oncogene
15:1979-1985[CrossRef][Medline].
|
| 29.
|
Gerondakis, S.,
R. Grumont,
I. Rourke, and M. Grossmann.
1998.
The regulation and roles of Rel/NF- B transcription factors during lymphocyte activation.
Curr. Opin. Immunol.
10:353-359[CrossRef][Medline].
|
| 30.
|
Ghosh, S.,
M. J. May, and E. B. Kopp.
1998.
NF- B and Rel proteins: evolutionarily conserved mediators of immune responses.
Annu. Rev. Immunol.
16:225-260[CrossRef][Medline].
|
| 31.
|
Gil, J.,
J. Alcami, and M. Esteban.
2000.
Activation of NF- B by the dsRNA-dependent protein kinase, PKR involves the I B kinase complex.
Oncogene
19:1369-1378[CrossRef][Medline].
|
| 32.
|
Gilmore, T. D.
1999.
Multiple mutations contribute to the oncogenicity of the retroviral oncoprotein v-Rel.
Oncogene
18:6925-6937[CrossRef][Medline].
|
| 33.
|
Givol, I.,
J. J. Greenhouse,
S. H. Hughes, and D. L. Ewert.
1992.
Retroviruses that express different ras mutants cause different types of tumors in chickens.
Oncogene
7:141-146[Medline].
|
| 34.
|
Grilli, M., and M. Memo.
1999.
Nuclear factor- B/Rel proteins: a point of convergence of signalling pathways relevant in neuronal function and dysfunction.
Biochem. Pharmacol.
57:1-7[CrossRef][Medline].
|
| 35.
|
Grossman, A.,
H.-W. Mittrücker,
J. Nicholl,
A. Suzuki,
S. Chung,
L. Antonio,
S. Suggs,
G. R. Sutherland,
D. P. Siderovski, and T. W. Mak.
1996.
Cloning of human lymphocyte-specific interferon regulatory factor (hLSIRF/hIRF4) and mapping of the gene to 6p23-p25.
Genomics
37:229-233[CrossRef][Medline].
|
| 36.
|
Grossmann, M.,
Y. Nakamura,
R. Grumont, and S. Gerondakis.
1999.
New insights into the roles of ReL/NF- B transcription factors in immune function, hemopoiesis and human disease.
Int. J. Biochem. Cell Biol.
31:1209-1219[CrossRef][Medline].
|
| 37.
|
Grumont, R. J., and S. Gerondakis.
2000.
Rel induces interferon regulatory factor 4 (IRF-4) expression in lymphocytes: modulation of interferon-regulated gene expression by Rel/nuclear factor B.
J. Exp. Med.
191:1281-1291[Abstract/Free Full Text].
|
| 38.
|
Haas, A. F.,
J. W. Wong,
C. K. Iwahashi,
B. Halliwell,
C. E. Cross, and P. A. Davis.
1998.
Redox regulation of wound healing? NF- B activation in cultured human keratinocytes upon wounding and the effect of low energy HeNe irradiation.
Free Radical Biol. Med.
25:998-1005[CrossRef][Medline].
|
| 39.
|
Harada, H.,
M. Kitagawa,
N. Tanaka,
H. Yamamoto,
K. Harada,
M. Ishihara, and T. Taniguchi.
1993.
Anti-oncogenic and oncogenic potentials of interferon regulatory factors-1 and -2.
Science
259:971-974[Abstract].
|
| 40.
|
Harada, H.,
T. Taniguchi, and N. Tanaka.
1998.
The role of interferon regulatory factors in the interferon system and cell growth control.
Biochimie
80:641-650[Medline].
|
| 41.
|
Holtschke, T.,
J. Löhler,
Y. Kanno,
T. Fehr,
N. Giese,
K.-P. Knobeloch,
L. Gabriele,
J. F. Waring,
M. F. Bachmann,
R. M. Zinkernagel,
H. C. Morse III,
K. Ozato, and I. Horak.
1996.
Immunodeficiency and chronic myelogenous leukemia-like syndrome in mice with a targeted mutation of the ICSBP gene.
Cell
87:307-317[CrossRef][Medline].
|
| 42.
|
Hrdli ková, R.,
J. Nehyba, and J. H. R. Bose.
1999.
Reticuloendotheliosis viruses (Retroviridae), p. 1496-1503.
In
A. Granoff, and R. G. Webster (ed.), Encyclopedia of virology, vol. 3. Academic Press, London.
|
| 43.
|
Hrdli ková, R.,
J. Nehyba, and E. H. Humphries.
1994.
In vivo evolution of c-rel oncogenic potential.
J. Virol.
68:2371-2382[Abstract/Free Full Text].
|
| 44.
|
Hrdli ková, R.,
J. Nehyba, and E. H. Humphries.
1994.
v-rel induces expression of three avian immunoregulatory surface receptors more efficiently than c-rel.
J. Virol.
68:308-319[Abstract/Free Full Text].
|
| 45.
|
Hrdli ková, R.,
J. Nehyba,
A. Roy,
E. H. Humphries, and H. R. Bose, Jr.
1995.
The relocalization of v-Rel from the nucleus to the cytoplasm coincides with induction of expression of Ikba and nfkb1 and stabilization of I B- .
J. Virol.
69:403-413[Abstract].
|
| 46.
|
Hughes, S. H.,
J. J. Greenhouse,
C. J. Petropoulos, and P. Sutrave.
1987.
Adaptor plasmids simplify the insertion of foreign DNA into helper-independent retroviral vectors.
J. Virol.
61:3004-3012[Abstract/Free Full Text].
|
| 47.
|
Iida, S.,
P. H. Rao,
M. Butler,
P. Corradini,
M. Boccadoro,
B. Klein,
R. S. K. Chaganti, and R. Dalla-Favera.
1997.
Deregulation of MUM1/IRF4 by chromosomal translocation in multiple myeloma.
Nat. Genet.
17:226-230[CrossRef][Medline].
|
| 48.
|
Jeanmougin, F.,
J. D. Thompson,
M. Gouy,
D. G. Higgins, and T. J. Gibson.
1998.
Multiple sequence alignment with Clustal X.
Trends Biochem. Sci.
23:403-405[CrossRef][Medline].
|
| 49.
|
Joklik, W. K.
1991.
Interferons, p. 343-370.
In
B. N. Fields, and D. M. Knipe (ed.), Fundamental virology, 2nd ed. Raven Press, New York, N.Y.
|
| 50.
|
Jungwirth, C.,
M. Rebbert,
K. Ozato,
H. J. Degen,
U. Schultz, and I. B. Dawid.
1995.
Chicken interferon consensus sequence-binding protein (ICSBP) and interferon regulatory factor (IRF) 1 genes reveal evolutionary conservation in the IRF family.
Proc. Natl. Acad. Sci. USA
92:3105-3109[Abstract/Free Full Text].
|
| 51.
|
Kanegae, Y.,
A. T. Tavares,
J. C. I. Belmonte, and I. M. Verma.
1998.
Role of Rel/NF- B transcription factors during the outgrowth of the vertebrate limb.
Nature
392:611-614[CrossRef][Medline].
|
| 52.
|
Kanno, Y.,
C. A. Kozak,
C. Schindler,
P. H. Driggers,
D. L. Ennist,
S. L. Gleason,
J. J. E. Darnell, and K. Ozato.
1993.
The genomic structure of the murine ICSBP gene reveals the presence of the gamma interferon-responsive element, to which an ISGF subunit (or similar) molecule binds.
Mol. Cell. Biol.
13:3951-3963[Abstract/Free Full Text].
|
| 53.
|
Kim, S.,
E. H. Humphries,
L. Tjoelker,
L. Carlson, and C. B. Thompson.
1990.
Ongoing diversification of the rearranged immunoglobulin light-chain gene in a bursal lymphoma cell line.
Mol. Cell. Biol.
10:3224-3231[Abstract/Free Full Text].
|
| 54.
|
Koerner, T. J.,
J. E. Hill,
A. M. Myers, and A. Tzagoloff.
1991.
High-expression vectors with multiple cloning sites for construction of trpE fusion genes: pATH vectors.
Methods Enzymol.
194:477-490[Medline].
|
| 55.
|
Köntgen, F.,
R. J. Grumont,
A. Strasser,
D. Metcalf,
R. Li,
D. Tarlinton, and S. Gerondakis.
1995.
Mice lacking the c-rel proto-oncogene exhibit defects in lymphocyte proliferation, humoral immunity, and interleukin-2 expression.
Genes Dev.
9:1965-1977[Abstract/Free Full Text].
|
| 56.
|
Kopp, E. B., and S. Ghosh.
1995.
NF- B and Rel proteins in innate immunity.
Adv. Immunol.
58:1-27[Medline].
|
| 57.
|
Kozak, M.
1987.
An analysis of 5'-noncoding sequences from 699 vertebrate messenger RNAs.
Nucleic Acids Res.
15:8125-8148[Abstract/Free Full Text].
|
| 58.
|
Kralova, J.,
A. S. Liss,
W. Bargmann, and H. R. Bose, Jr.
1998.
AP-1 factors play an important role in transformation induced by the v-rel oncogene.
Mol. Cell. Biol.
18:2997-3009[Abstract/Free Full Text].
|
| 59.
|
Kralova, J.,
J. D. Schatzle,
W. Bargmann, and H. R. Bose, Jr.
1994.
Transformation of avian fibroblasts overexpressing the c-rel proto-oncogene and a variant of c-rel lacking forty C-terminal amino acids.
J. Virol.
68:2073-2083[Abstract/Free Full Text].
|
| 60.
|
Kumar, K. P.,
K. M. McBride,
B. K. Weaver,
C. Dingwall, and N. C. Reich.
2000.
Regulated nuclear-cytoplasmic localization of interferon regulatory factor 3, a subunit of double-stranded RNA-activated factor 1.
Mol. Cell. Biol.
20:4159-4168[Abstract/Free Full Text].
|
| 61.
|
Lawrence, C. E.,
S. F. Altschul,
M. S. Boguski,
J. S. Liu,
A. F. Neuwald, and J. C. Wootton.
1993.
Detecting subtle sequence signals: a Gibbs sampling strategy for multiple alignment.
Science
262:208-214[Abstract/Free Full Text].
|
| 62.
|
Lewis, R. B.,
J. McClure,
B. Rup,
D. W. Niesel,
R. F. Garry,
J. D. Hoelzer,
K. Nazerian, and H. R. Bose, Jr.
1981.
Avian reticuloendotheliosis virus: identification of the hematopoietic target cell for transformation.
Cell
25:421-431[CrossRef][Medline].
|
| 63.
|
Li, W.,
C. N. Nagineni,
B. Efiok,
A. B. Chepelinsky, and C. E. Egwuagu.
1999.
Interferon regulatory transcription factors are constitutively expressed and spatially regulated in the mouse lens.
Dev. Biol.
210:44-55[CrossRef][Medline].
|
| 64.
|
Li, W.,
C. N. Nagineni,
J. J. Hooks,
A. B. Chepelinsky, and C. E. Egwuagu.
1999.
Interferon- signaling in human retinal pigment epithelial cells mediated by STAT1, ICSBP, and IRF-1 transcription factors.
Investig. Ophthalmol. Vis. Sci.
40:976-982[Abstract/Free Full Text].
|
| 65.
|
Lubyova, B., and P. M. Pitha.
2000.
Characterization of a novel human herpesvirus 8-encoded protein, vIRF-3, that shows homology to viral and cellular interferon regulatory factors.
J. Virol.
74:8194-8201[Abstract/Free Full Text].
|
| 66.
|
Mamane, Y.,
C. Heylbroeck,
P. Genin,
M. Algarte,
M. J. Servant,
C. LePage,
C. DeLuca,
H. Kwon,
R. Lin, and J. Hiscott.
1999.
Interferon regulatory factors: the next generation.
Gene
237:1-14[CrossRef][Medline].
|
| 67.
|
Marecki, S.,
M. L. Atchison, and M. J. Fenton.
1999.
Differential expression and distinct functions of IFN regulatory factor 4 and IFN consensus sequence binding protein in macrophages.
J. Immunol.
163:2713-2722[Abstract/Free Full Text].
|
| 68.
|
Matsuyama, T.,
A. Grossman,
H. W. Mittrucker,
D. P. Siderovski,
F. Kiefer,
T. Kawakami,
C. D. Richardson,
T. Taniguchi,
S. K. Yoshinaga, and T. W. Mak.
1995.
Molecular cloning of LSIRF, a lymphoid-specific member of the interferon regulatory factor family that binds the interferon-stimulated response element (ISRE).
Nucleic Acids Res.
23:2127-2136[Abstract/Free Full Text].
|
| 69.
|
Mellon, P.,
V. Parker,
Y. Gluzman, and T. Maniatis.
1981.
Identification of DNA sequences required for transcription of the human alpha 1-globin gene in a new SV40 host-vector system.
Cell
27:279-288[CrossRef][Medline].
|
| 70.
|
Meric, C., and P. F. Spahr.
1986.
Rous sarcoma virus nucleic acid-binding protein p12 is necessary for viral 70S RNA dimer formation and packaging.
J. Virol.
60:450-452[Abstract/Free Full Text].
|
| 71.
|
Mittrücker, H.-W.,
T. Matsuyama,
A. Grossman,
T. M. Kündig,
J. Potter,
A. Shahinian,
A. Wakeham,
B. Patterson,
P. S. Ohashi, and T. W. Mak.
1997.
Requirement for the transcription factor LSIRF/IRF4 for mature B and T lymphocyte function.
Science
275:540-543[Abstract/Free Full Text].
|
| 72.
|
Moore, B. E., and H. R. Bose, Jr.
1988.
Expression of the v-rel oncogene in reticuloendotheliosis virus-transformed fibroblasts.
Virology
162:377-387[CrossRef][Medline].
|
| 73.
|
Mora, A. L.,
D. Chen,
M. Boothby, and D. H. Rubin.
1999.
Lineage-specific differences among CD8+ T cells in their dependence of NF- B/Rel signaling.
Eur. J. Immunol.
29:2968-2980[CrossRef][Medline].
|
| 74.
|
Morrison, L. E.,
G. Boehmelt,
H. Beug, and P. J. Enrietto.
1991.
Expression of v-rel in a replication competent virus: transformation and biochemical characterization.
Oncogene
6:1657-1666[Medline].
|
| 75.
|
Morrison, L. E.,
G. Boehmelt, and P. J. Enrietto.
1992.
Mutations in the rel-homology domain alter the biochemical properties of v-rel and render it transformation defective in chicken embryo fibroblasts.
Oncogene
7:1137-1147[Medline].
|
| 76.
|
Moscovici, C.,
M. G. Moscovici,
H. Jimenez,
M. M. Lai,
M. J. Hayman, and P. K. Vogt.
1977.
Continuous tissue culture cell lines derived from chemically induced tumors of Japanese quail.
Cell
11:95-103[CrossRef][Medline].
|
| 77.
|
Moscovici, C.,
N. Zeller, and M. G. Moscovici.
1982.
Continuous lines of AMV-transformed nonproducer cells: growth and oncogenic potential in the chick embryo, p. 435-449.
In
R. F. Revoltella, et al. (ed.), Expression of differentiated functions in cancer cells. Raven Press, New York, N.Y.
|
| 78.
|
Mosialos, G.,
P. Hamer,
A. J. Capobianco,
R. A. Laursen, and T. D. Gilmore.
1991.
A protein kinase A recognition sequence is structurally linked to transformation by p59v-rel and cytoplasmic retention of p68c-rel.
Mol. Cell. Biol.
11:5867-5877[Abstract/Free Full Text].
|
| 79.
|
Nagulapalli, S., and M. L. Atchison.
1998.
Transcription factor Pip can enhance DNA binding by E47, leading to transcriptional synergy involving multiple protein domains.
Mol. Cell. Biol.
18:4639-4650[Abstract/Free Full Text].
|
| 80.
|
Nazerian, K.,
E. A. Stephens,
J. M. Sharma,
L. M. Lee,
M. Gailitis, and R. I. Witter.
1977.
A nonproducer T lymphoblastoid cell line from Marek's disease transplantable tumor (JMV).
Avian Dis.
21:69-76[CrossRef][Medline].
|
| 81.
|
Nehyba, J.,
R. Hrdli ková, and E. H. Humphries.
1994.
Evolution of the oncogenic potential of v-rel: rel-induced expression of immunoregulatory receptors correlates with tumor development and in vitro transformation.
J. Virol.
68:2039-2050[Abstract/Free Full Text].
|
| 82.
|
Nehyba, J.,
J. Svoboda,
I. Karakoz,
J. Geryk, and J. Hejnar.
1990.
Ducks: a new experimental host system for studying persistent infection with avian leukaemia retroviruses.
J. Gen. Virol.
71:1937-1945[Abstract/Free Full Text].
|
| 83.
|
Nguyen, H.,
J. Hiscott, and P. M. Pitha.
1997.
The growing family of interferon regulatory factors.
Cytokine Growth Factor Rev.
8:293-312[CrossRef][Medline].
|
| 84.
|
Okuno, H.,
T. Suzuki,
T. Yoshida,
Y. Hashimoto,
T. Curran, and H. Iba.
1991.
Inhibition of jun transformation by a mutated fos gene: design of an anti-oncogene.
Oncogene
6:1491-1497[Medline].
|
| 85.
|
Pahl, H. L.
1999.
Activators and target genes of Rel/NF- B transcription factors.
Oncogene
18:6853-6866[CrossRef][Medline].
|
| 86.
|
Pearson, W. R., and D. J. Lipman.
1988.
Improved tools for biological sequence comparison.
Proc. Natl. Acad. Sci. USA
85:2444-2448[Abstract/Free Full Text].
|
| 87.
|
Petrenko, O.,
I. Ischenko, and P. J. Enrietto.
1997.
Characterization of changes in gene expression associated with malignant transformation by the NF- B family member, v-Rel.
Oncogene
15:1671-1680[CrossRef][Medline].
|
| 88.
|
Pitha, P. M.,
W. C. Au,
W. Lowther,
Y. T. Juang,
S. L. Schafer,
L. Burysek,
J. Hiscott, and P. A. Moore.
1998.
Role of the interferon regulatory factors (IRFs) in virus-mediated signaling and regulation of cell growth.
Biochimie
80:651-658[Medline].
|
| 88a.
|
Plachy, J.,
K. C. Weining,
E. Kremmer,
F. Puehler,
K. Hala,
B. Kaspers, and P. Staeheli.
1999.
Protective effects of type I and type II interferons toward Rous sarcoma virus-induced tumors in chickens.
Virology
256:85-91[CrossRef][Medline].
|
| 89.
|
Rao, A.,
K. Kline, and B. G. Sanders.
1990.
Immune abnormalities in avian ertythroblastosis virus-infected chickens.
Cancer Res.
50:4764-4770[Abstract/Free Full Text].
|
| 90.
|
Rayet, B., and C. Gelinas.
1999.
Aberrant rel/nfkb genes and activity in human cancer.
Oncogene
18:6938-6947[CrossRef][Medline].
|
| 91.
|
Reboul, J.,
K. Gardiner,
D. Monneron,
G. Uze, and G. Lutfalla.
1999.
Comparative genomic analysis of the interferon/interleukin-10 receptor gene cluster.
Genome Res.
9:242-250[Abstract/Free Full Text].
|
| 92.
|
Rechsteiner, M., and S. W. Rogers.
1996.
PEST sequences and regulation by proteolysis.
Trends Biochem. Sci.
21:267-271[CrossRef][Medline].
|
| 93.
|
Romero, P., and E. H. Humphries.
1995.
A mutant v-rel with increased ability to transform B lymphocytes.
J. Virol.
69:301-307[Abstract].
|
| 94.
|
Rosenbauer, F.,
J. F. Waring,
J. Foerster,
M. Wietstruk,
D. Philipp, and I. Horak.
1999.
Interferon consensus sequence binding protein and interferon regulatory factor-4/Pip form a complex that represses the expression of the interferon-stimulated gene-15 in macrophages.
Blood
94:4274-4281[Abstract/Free Full Text].
|
| 95.
|
Saito, T.,
T. Yamagata,
T. Takahashi,
H. Honda, and H. Hirai.
1999.
ICSAT overexpression is not sufficient to cause adult T-cell leukemia or multiple myeloma.
Biochem. Biophys. Res. Commun.
260:329-331[CrossRef][Medline].
|
| 96.
|
Schaper, F.,
S. Kirchhoff,
G. Posern,
M. Köster,
A. Oumard,
R. Sharf,
B. Z. Levi, and H. Hauser.
1998.
Functional domains of interferon regulatory factor I (IRF-1).
Biochem. J.
335:147-157.
|
| 97.
|
Schmidt, M.,
S. Nagel,
J. Proba,
C. Thiede,
M. Ritter,
J. F. Waring,
F. Rosenbauer,
D. Huhn,
B. Wittig,
I. Horák, and A. Neubauer.
1998.
Lack of interferon consensus sequence binding protein (ICSBP) transcripts in human myeloid leukemia.
Blood
91:22-29[Abstract/Free Full Text].
|
| 98.
|
Schuler, G. D.,
S. F. Altschul, and D. J. Lipman.
1991.
A workbench for multiple alignment construction and analysis.
Proteins
9:180-190[CrossRef][Medline].
|
| 99.
|
Schultz, U.,
C. Rinderle,
M. J. Sekellick,
P. I. Marcus, and P. Staeheli.
1995.
Recombinant chicken interferon from Escherichia coli and transfected COS cells is biologically active.
Eur. J. Biochem.
229:73-76[Medline].
|
| 100.
|
Schwartz, R. C., and O. N. Witte.
1988.
A recombinant murine retrovirus expressing v-rel is cytopathic.
Virology
165:182-190[CrossRef][Medline].
|
| 101.
|
Sick, C.,
U. Schultz,
U. Munster,
J. Meier,
B. Kaspers, and P. Staeheli.
1998.
Promoter structures and differential responses to viral and nonviral inducers of chicken type I interferon genes.
J. Biol. Chem.
273:9749-9754[Abstract/Free Full Text].
|
| 102.
|
Sick, C.,
U. Schultz, and P. Staeheli.
1996.
A family of genes coding for two serologically distinct chicken interferons.
J. Biol. Chem.
271:7635-7639[Abstract/Free Full Text].
|
| 103.
|
Stark, G. R.,
I. M. Kerr,
B. R. Williams,
R. H. Silverman, and R. D. Schreiber.
1998.
How cells respond to interferons.
Annu. Rev. Biochem.
67:227-264[CrossRef][Medline].
|
| 104.
|
Stoker, A. W., and M. J. Bissell.
1987.
Quantitative immunocytochemical assay for infectious avian retroviruses.
J. Gen. Virol.
68:2481-2485[Abstract/Free Full Text].
|
| 105.
|
Stone, E. M.,
K. N. Rothblum,
M. C. Alevy,
T. M. Kuo, and R. J. Schwartz.
1985.
Complete sequence of the chicken glyceraldehyde-3-phosphate dehydrogenase gene.
Proc. Natl. Acad. Sci. USA
82:1628-1632[Abstract/Free Full Text].
|
| 106.
|
Tirunagaru, V. G.,
L. Sofer,
J. Cui, and J. Burnside.
2000.
An expressed sequence tag database of T-cell-enriched activated chicken splenocytes: sequence analysis of 5251 clones.
Genomics
66:144-151[CrossRef][Medline].
|
| 107.
|
Wathelet, M. G.,
C. H. Lin,
B. S. Parekh,
L. V. Ronco,
P. M. Howley, and T. Maniatis.
1998.
Virus infection induces the assembly of coordinately activated transcription factors on the IFN- enhancer in vivo.
Mol. Cell
1:507-518[CrossRef][Medline].
|
| 108.
|
Yamagata, T.,
J. Nishida,
T. Tanaka,
R. Sakai,
K. Mitani,
M. Yoshida,
T. Taniguchi,
Y. Yazaki, and H. Hirai.
1996.
A novel interferon regulatory factor family transcription factor, ICSAT/Pip/LSIRF, that negatively regulates the activity of interferon-regulated genes.
Mol. Cell. Biol.
16:1283-1294[Abstract].
|
| 109.
|
Yamamoto, A.,
A. Iwata,
Y. Koh,
S. Kawai,
S. Murayama,
K. Hamada,
S. Maekawa,
S. Ueda, and Y. Sokawa.
1998.
Two types of chicken 2',5'-oligoadenylate synthetase mRNA derived from alleles at a single locus.
Biochim. Biophys. Acta
1395:181-191[Medline].
|
| 110.
|
Yoshida, S.,
N. Nakazawa,
S. Iida,
Y. Hayami,
S. Sato,
A. Wakita,
S. Shimizu,
M. Taniwaki, and R. Ueda.
1999.
Detection of MUM1/IRF4-IgH fusion in multiple myeloma.
Leukemia
13:1812-1816[CrossRef][Medline].
|
| 111.
|
Zhang, J. Y., and H. R. Bose, Jr.
1989.
Acquisition of new proviral copies in avian lymphoid cells transformed by reticuloendotheliosis virus.
J. Virol.
63:1107-1115[Abstract/Free Full Text].
|
| 112.
|
Zhang, L., and J. S. Pagano.
1997.
IRF-7, a new interferon regulatory factor associated with Epstein-Barr virus latency.
Mol. Cell. Biol.
17:5748-5757[Abstract].
|
| 113.
|
Zong, C. S.,
J. L.-K. Chan,
S.-K. Yang, and L.-H. Wang.
1997.
Mutations of Ros differentially effecting signal transduction pathways leading to cell growth versus transformation.
J. Biol. Chem.
272:1500-1506[Abstract/Free Full Text].
|
Molecular and Cellular Biology, October 2001, p. 6369-6386, Vol. 21, No. 19
0270-7306/01/$04.00+0 DOI: 10.1128/MCB.21.19.6369-6386.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Hrdlickova, R., Nehyba, J., Bose, H. R. Jr.
(2009). Regulation of Telomerase Activity by Interferon Regulatory Factors 4 and 8 in Immune Cells. Mol. Cell. Biol.
29: 929-941
[Abstract]
[Full Text]
-
Gupta, N., Delrow, J., Drawid, A., Sengupta, A. M., Fan, G., Gelinas, C.
(2008). Repression of B-Cell Linker (BLNK) and B-Cell Adaptor for Phosphoinositide 3-Kinase (BCAP) Is Important for Lymphocyte Transformation by Rel Proteins. Cancer Res.
68: 808-814
[Abstract]
[Full Text]
-
Ramos, J. C., Ruiz, P. Jr, Ratner, L., Reis, I. M., Brites, C., Pedroso, C., Byrne, G. E. Jr, Toomey, N. L., Andela, V., Harhaj, E. W., Lossos, I. S., Harrington, W. J. Jr
(2007). IRF-4 and c-Rel expression in antiviral-resistant adult T-cell leukemia/lymphoma. Blood
109: 3060-3068
[Abstract]
[Full Text]
-
Hrdlickova, R., Nehyba, J., Liss, A. S., Bose, H. R. Jr.
(2006). Mechanism of Telomerase Activation by v-Rel and Its Contribution to Transformation. J. Virol.
80: 281-295
[Abstract]
[Full Text]
-
Lin, L., Gerth, A. J., Peng, S. L.
(2004). Active Inhibition of Plasma Cell Development in Resting B Cells by Microphthalmia-associated Transcription Factor. JEM
0: jem.20040612--D8
[Abstract]
[Full Text]
-
Rayet, B., Fan, Y., Gelinas, C.
(2003). Mutations in the v-Rel Transactivation Domain Indicate Altered Phosphorylation and Identify a Subset of NF-{kappa}B-Regulated Cell Death Inhibitors Important for v-Rel Transforming Activity. Mol. Cell. Biol.
23: 1520-1533
[Abstract]
[Full Text]
-
Kralova, J., Liss, A. S., Bargmann, W., Pendleton, C., Varadarajan, J., Ulug, E., Bose, H. R. Jr.
(2002). Differential Regulation of the Inhibitor of Apoptosis ch-IAP1 by v-rel and the Proto-Oncogene c-rel. J. Virol.
76: 11960-11970
[Abstract]
[Full Text]
-
Martinez, J. M., Afshari, C. A., Bushel, P. R., Masuda, A., Takahashi, T., Walker, N. J.
(2002). Differential Toxicogenomic Responses to 2,3,7,8-Tetrachlorodibenzo-p-dioxin in Malignant and Nonmalignant Human Airway Epithelial Cells. Toxicol Sci
69: 409-423
[Abstract]
[Full Text]
-
Nehyba, J., Hrdlickova, R., Burnside, J., Bose, H. R. Jr.
(2002). A Novel Interferon Regulatory Factor (IRF), IRF-10, Has a Unique Role in Immune Defense and Is Induced by the v-Rel Oncoprotein. Mol. Cell. Biol.
22: 3942-3957
[Abstract]
[Full Text]